

Curriculum Vitae 2023

Name: Frederick William Miller, M.D., Ph.D.

Citizenship: United States

Present Address: Scientist Emeritus, Environmental Autoimmunity Group
Clinical Research Branch
National Institute of Environmental Health Sciences
P.O. Box 12233, Mail Drop A2-03
111 TW Alexander Drive
Research Triangle Park, North Carolina 27709
millerf@mail.nih.gov
Phone: 984-287-3593

Education

1969 Salutatorian, Troy High School, Troy, OH

1973 **B.A.**, Zoology, with minor in Chemistry, *Summa cum laude*,
General Honors, Miami University, Oxford, OH

1979 **M.D., Ph.D.**, Medical Scientist Training Program, Department
of Anatomy and Developmental Biology Center, Case Western
Reserve University School of Medicine, Cleveland, OH

Licensure and Certification

1980 National Board of Medical Examiners

1981 California Medical License #45861

1983 Maryland Medical License #D30329

1983 Board Certified in Internal Medicine by American Board of
Internal Medicine

1990 Board Certified in Rheumatology by the American Board of
Internal Medicine

Employment and Experience

07/1979-06/1980 Medical Intern - Department of Medicine, Emory University
School of Medicine Affiliated Hospitals, Atlanta, GA

07/1980-06/1981 Clinical Research Fellow - Clinical Research Facility, Emory
University Medical Center, Atlanta, GA

07/1981-06/1983 Medical Resident - Department of Medicine, Stanford
University Medical Center, Stanford, CA

07/1983-07/1986 Medical Staff Fellow (Rheumatology Fellowship) - Arthritis
and Rheumatism Branch, NIAMS, NIH, Bethesda, MD

08/1986-11/1990 Senior Staff Fellow and Clinical Associate - Arthritis and
Rheumatism Branch, NIAMS, NIH, Bethesda, MD

12/1990-09/1993	Senior Investigator and Medical Officer - Clinical and Product Reviewer, Division of Biochemistry and Biophysics, CBER, FDA, Bethesda, MD
10/1993-10/1996	Senior Investigator and Medical Officer – Clinical and Product Reviewer, Molecular Immunology Laboratory, Division of Cellular and Gene Therapies, CBER, FDA; Tenured Senior Investigator, US Public Health Service Research Officer Group in 1994
11/1996-12/2000	Senior Investigator and Medical Officer – Clinical and Product Reviewer, Laboratory of Molecular and Developmental Immunology, Division of Monoclonal Antibodies, CBER, FDA, Bethesda, MD
10/2011-02/2013	Acting Clinical Director, NIEHS
04/1991-04/2014	Captain, US Public Health Service Research Officer Group (retired 4/2014)
01/2001-10/2020	Chief, Environmental Autoimmunity Group, Clinical Research Branch, DIR, NIEHS, NIH, Bethesda, MD, Tenured Senior Investigator (retired)
10/2014-04/2021	Deputy Chief, Clinical Research Branch, NIEHS (retired 4/2021)
04/2021-present	Scientist Emeritus, NIEHS, NIH

Honors and Awards

1969	Bausch and Lomb Science Award, Troy High School
1969-70	John Rawlings Memorial Scholarships, Miami University
1971	Elected to Phi Beta Sigma Honor Society, Miami University
1971-72	Alan Brewer Memorial Scholarships, Miami University
1972	Culler Physics Award, Miami University
1973	Selected as NIH Trainee - Fertilization & Gamete Physiology Training Program, Marine Biology Laboratory, Woods Hole, MA
1973	B.A., Summa cum laude, General Honors, Miami University
1973	Elected to Phi Beta Kappa Honor Society, Miami University
1973	Hughes Chemistry Award, Miami University
1973-77	National Research Service Awards, Case Western Reserve University
1979	Hughes Research Award, Case Western Reserve University
1985	Selected as Fellow, American College of Physicians
1986	Senior Fellow Research Award, American College of Rheumatology
1989	William R. Felts Award for Excellence in Rheumatology Research
1992, 1997	FDA Office of Woman's Health grant recipient
1994	Selected as Fellow, American College of Rheumatology
1998	US Public Health Service National Vaccine Program Award

1998	US Public Health Service Unit Commendation Medal
1999	US Public Health Service Meritorious Service Medal
1999	US Public Health Service Outstanding Unit Citation
2000	Elected member of the Henry Kunkel Society
2000	First elected to Best Doctors in America
2003	The Kovacs Lectureship, the Royal Society of Medicine, London, UK
2005	The Dunlop-Dotteridge Lectureship, Canadian Rheumatology Association, Mt. Tremblant, Canada
2005	NIH Merit Award for participation on the NIEHS Strategic Planning Workgroup
2007	Hero Award, the Cure Juvenile Myositis Foundation, for "Dedication to Finding a Cure for Juvenile Myositis"
2008	Selected for listing in American Men and Women of Science
2013	US Public Health Service Achievement Medal
2014	National Institutes of Health Cross-Divisional Group Merit Award
2016	Selected as Master, American College of Rheumatology
2017	Global Conference on Myositis Achievement Award for Leadership in Myositis
2017	NIEHS Group Merit Award for Advancing Inflammation Biology Awareness
2019	Accepted the Global Genes RARE Champion of Hope Award on behalf of the International Myositis Assessment and Clinical Studies Group (IMACS)
2020	NICHHD Director's Award for work on the trans-IC COVID-19 Maternal and Child Health Subgroup
2022	The Myositis Association Scientific Hero Award

Societies

Fellow and Master, American College of Rheumatology
 Fellow, American College of Physicians
 Member, American Association of Immunologists
 Member, Henry Kunkel Society

Selected Editorial Activities

Editorial Board, *Annals of the Rheumatic Diseases*, 2017-present
 Associate Editor, *Journal of Neuromuscular Diseases*, 2013-present
 Editorial Board, *PLoS ONE*, 2011-present
 Associate Editor, *The Open Rheumatology Journal*, Bentham Science Publishers Ltd., 2007- present
 Co-Editor, *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, The Myositis Association, Washington, 2007

Section Editor, Muscle Disease, in *Practice Rheumatology*, Clinical Care Options LLC, 2012-2000

Section Editor, Inflammatory Myopathies, *Rheumatic Disease Clinics of North America*, 2001-2002

Section Editor, Myositis and Myopathies, *Current Opinion in Rheumatology*, 1995-1998

Ad hoc Reviewer for Journals (Selected Recent Examples)

Annals of Internal Medicine, Annals of Neurology, Annals of the Rheumatic Diseases, Arthritis & Rheumatology, Arthritis Care & Research, Arthritis Research and Therapy, Clinical Immunology, Drugs, Environmental Health Insights, Journal of Clinical Investigation, Journal of Clinical Rheumatology, Journal of Rheumatology, Lancet Neurology, Lupus, Nature Communications, Nature Medicine, Nature Reviews Rheumatology, Neuromuscular Disorders, PLoS ONE, Proceedings of the National Academy of Sciences, Rheumatology

Selected Scientific Leadership and Committee Work

NIH, FDA and other Federal Agencies

1985-Present	Member, NIH Immunology Interest Group
1985-2019	Associate Investigator, the NIAMS Natural History of Myositis Study
1986-1989	Principal Investigator, the NIAMS Cyclophosphamide in Myositis Trial
1986-1990	Principal Investigator, the NIAMS Apheresis in Myositis Trial
1987-1997	Principal Investigator, the NIAMS High Dose Methotrexate in Myositis Study
1988-1993	Associate Investigator, the NIAMS Familial Autoimmunity Study
1990-2001	Medical Staff Guest Worker, Principal Clinical Investigator, NIH Clinical Center, Arthritis and Rheumatism Branch, NIAMS
1990-2002	Product IND and BLA Reviewer, Division of Cell and Gene Therapy and Div. of Monoclonal Antibodies, CBER, FDA
1990-2002	Advisor, FDA Office of the Commissioner and FDA Centers Coordination Committee – focusing on regulatory issues relating to autoimmunity and genetic risk factors for adverse events
1991-2002	Member, FDA FiRST Initiative
1992-1995	Chair, Rheumatology Focus Group, Division of Clinical Trials, CBER, FDA
1992-1999	Member, DHHS Silicone Breast Implant Research Task Force
1992-1999	Project leader and author, FDA Guidance to Industry regarding the pilot eIND Program
1993-2005	Principal Investigator, the FDA Myositis Developing after Vaccination Study
1993-2005	Principal Investigator, the FDA Natural History of Autoimmune Diseases Study

1993-2003 Principal Investigator, the FDA Myeloma and MGUS following Silicone Implants Study

1993-2003 Principal Investigator, the FDA Myositis Developing after Silicone Implants Study

1993-1995 Chair, FDA Gene Therapy Information Network Working Group

1994-2002 Clinical IND and BLA Reviewer, Division of Clinical Trials, CBER, FDA

1994-2002 Member, FDA Rheumatology Working Group

1994-1998 Member, IRB Committee, Walter Reed Army Medical Center, Washington DC

1995-2005 Principal Investigator, the FDA Silicone-associated Connective Tissue Disease Study

1995-1999 Chair, FDA Electronic IND (eIND) Working Group

1996-1998 Member, FDA IND Communications Working Group

1996-2000 Elected representative, Committee to Advance CBER Science, FDA

1996-2000 Member, Armed Forces Institute of Pathology Scientific Advisory Board, Washington, DC

1997-1998 Chair, FDA Biologics Licensing Application Committee, Simulect

1997-2002 Member, DHHS Interagency Temporal Mandibular Disorder Working Group

1997-1998 Project member and contributing author, FDA Guidance to Industry regarding electronic submissions of patient case report forms and case report tabulations

1998-1999 Project member and co-author, FDA Guidance to Industry regarding developing therapies for rheumatoid arthritis

1999-2002 Reviewer, Veterans Administration Research Merit Review Board

1999-2002 Principal Investigator, the Familial Myositis Study

1999-2016 Associate Investigator, the NIAMS Infliximab in Myositis Study

2000-2004 Member, FDA Vascular Injury Expert Working Group

2001-2009 Associate Investigator, the FDA Rheumatoid Arthritis after Lyme Vaccine Study

2001-Present Collaborator, the NIEHS Natural History of Adult and Juvenile Myositis Study

2001-2021 Alternate Member, NIH Medical Executive Committee

2002 Member, NIEHS Search Committee, Staff Clinician, Environmental Autoimmunity Group

2002-2008 Associate Investigator, the NIDR Soft Tissue Calcification Study

2003-2021 Principal Investigator, the NIEHS Twin-siblings Systemic Autoimmunity Study

2003 Member, NIEHS Search Committee, Tenure-Track Clinical Investigator in Gynecology

2003-2011 Member, NIH Chronic Graft-Versus-Host Disease Response Criteria Working Group

2003-2005	Member, NIH Roadmap Regional Translational Research Center Working Group
2003-2005	Member, NIH Roadmap Translational Core Working Group
2005-2010	Member, NIH Roadmap Clinical and Translational Sciences Working Group
2005-2015	Member, Trans-NIH Bioethics Committee
2005-2021	Member, NIEHS Clinical Advisory Committee
2005-2006	Member, NIEHS Strategic Planning Forum Steering Committee
2005	Member, NIEHS Search Committee, Tenure-Track Clinical Investigator in Host Defense
2005-2021	Principal Investigator, the NIEHS Natural History of Autoimmune Diseases Study
2006-2019	Principal Investigator and Steering Committee Member, the NIEHS Rituximab in Myositis Trial
2006	Member, NIEHS Search Committee, Staff Clinician, Clinical Research Unit
2006-2014	Member, NIH National Quality Forum
2006-2017	Member, NIH Clinical Research Center Medicine Partners Committee
2007-2020	Member, NIH Center for Human Immunology Scientific Advisory Committee
2008-2017	Member, NIH Translational Research Interest Group Steering Committee
2008-2016	Member, NIH Biomedical Translational Research Information System (BTRIS) Group
2008-2020	Member, NIEHS Clinical Advisory Committee
2008-2020	Chair, NIEHS Clinical Center Utilization Review Committee
2009-2017	Member, NIEHS Clinical Research Unit Contract Resource Review Committee
2010-2021	Principal Investigator, the NIEHS Environmental Factors in the Anti-synthetase Syndrome; Associate Investigator since 2021
2010-2011	Member, NIEHS Search Committee, EAG Staff Clinician
2010-2018	Member, NIEHS Committee on Tenure and Promotions (COP I)
2010-Present	Founder and Chair, The NHANES Autoimmunity Study Group
2011-2021	Member, NIEHS Environmental Polymorphism Registry Steering Committee
2011-2012	Chair, NIEHS Search Committees, EAG and Clinical Research Unit Staff Clinicians
2011-2016	Member, NIEHS Title 42 Pay Committee
2011-2014	Member, NIEHS Search Committee, Clinical Director NIEHS
2012-2021	Principal Investigator, the NIEHS Environmental Factors in Myositis in the Military; Associate Investigator since 2021
2012-2014	Member, NIH Earl Stadtman Investigator Review Committee on Immunology

2010-2020	Member, Trans-NIH Outcomes-Effectiveness Research Interest Group (OER-IG)
2012-2015	Member, NIH Clinical Trials Working Group
2012-2019	Co-Lead, NIEHS Inflammation Cross-Divisional Implementation Working Group
2013-2017	Member, NIH Translational Research Information System Data Access Committee
2014-2019	Member, NIH IRP Population Science Working Group
2016-2017	Member, Veterans Administration Epidemiology Scientific Review Group
2016-2017	NIH Deputy Director Representative, NCI Search Committee, Tenure-track Environmental Exposure Assessor
2017-Present	Collaborator, the Sodium Thiosulfate in Calcinosis Trial
2017-2018	Member, Search Committee, Chief, Immunology Service, NIH Clinical Center
2018	Chair, NIEHS IT Committee on NIEHS Clinical Needs
2018	Chair, Search Committee, Senior Medical Advisor, NIEHS Office of the Director
2018-2019	Member, Search Committees, Research Nurses, NIEHS Clinical Research Unit
2019	Chair, Search Committee, Supervisory Research Nurse, NIEHS Clinical Research Unit
2019	Member, NIEHS Advisory Committee on Recruitment of the Director of the Office of Technology Transfer
2019-2021	Member, NIEHS Committee on Promotion IV (COP IV)
2019-Present	Founder and Chair, NIEHS Personalized Environment and Genes Study Immune-Mediated Disease Study Group
2019-2021	Member, Search Committee, Tenure track investigator, NIEHS Clinical Research Branch
2020-2021	Member, Search Committee, Tenure track investigator, NIEHS Immunity, Inflammation and Disease Laboratory
2020	Member, Search Committee, Staff Clinician, NIEHS Clinical Research Branch
2020-2021	Member, NIEHS Protocol Scientific Review Committee
2021	Member, NIEHS Cross-Divisional Faculty Proposal Scientific Review Committee

Nationally and Internationally

1990-2016	Member, ACR National Meeting Myositis Abstract Selection Committees
1993-2000	Founder and Director, the International Myositis Collaborative Study Group
1994-1999	Founder and Chair, American College of Rheumatology Environmentally Associated Rheumatic Diseases Study Group

1994-1996	Board Member/Advisor, the National Dermatomyositis Support Group
1995-2021	Co-Founder, the Childhood Myositis Heterogeneity Collaborative Study Group
1996-1998	Presenter, ACR Meet the Expert Series, Myositis and Myopathies
1996-2003	Member, NIAMS Juvenile Dermatomyositis Registry Advisory Board
1996-2005	Member, OMERACT Toxicity Assessment Task Force
1996-2003	Invited Presenter, NAS Institute of Medicine Silicone Scientific Review Committee
2000-2004	Member, Board of Directors and Medical Advisory Board Vice-Chair, The Myositis Association
2000-2008	Member, Medical Advisory Board, The Myositis Association
2000-2015	Founder and Director, the Environmental Myositis Collaborative Study Group
2001-2002	Presenter, ACR Meet the Professor Series, Myositis and Myopathies
2002-2019	Member, Steering Committee, The NIAMS Rituximab in Myositis Trial
2004-2009	Member, Adjudication Committee, The NIAMS Rituximab in Myositis Trial
2004-2014	Scientific Reviewer, The Myositis Association Grants Program
2004-2019	Member, Research Review Committee, The NIAMS Rituximab in Myositis Trial
2005-2006	Category Chair, Myositis and Myopathies, American College of Rheumatology National Meeting Abstract Selection Committee
2007-2008	Member, Nominations Committee, The Myositis Association
2007-2016	Co-Founder and Co-Director, The Pan-American Congress of Rheumatism (PANLAR) Myositis Consortium
2009-2019	Member, Publications Committee, the NIAMS Rituximab in Myositis Trial
2009-2011	Member, Scientific Work Group, National Conversation on Public Health and Chemical Exposures
2009-2014	Chair, The International Myositis Assessment and Clinical Studies Group (IMACS) Scientific Committee; 2015-present: Member as former Chair
2009-2019	Member, Connective Tissue Disease Related Interstitial Pulmonary Fibrosis OMERACT Group
2010-2013	Category Chair, Myositis and Myopathies, American College of Rheumatology National Meeting Abstract Selection Committee
2014-2021	Unpaid Medical Advisor to aTyr, MedImmune, Momenta and Idera Pharma
2008-2021	Scientific Advisor, The George Washington University Myositis Clinic

2012–2021	Member, Steering Committee, ACR-EULAR-IMACS-PRINTO Response Criteria Project for Adult and Juvenile Dermatomyositis and Polymyositis
2013-2014	Reviewer for Inflammation Initiative, Canadian Institutes of Health Research
2003-2017	Co-Organizer and Member, Steering Committee, ACR-EULAR International Myositis Classification Criteria Project
2000-2021	Co-Founder and Co-Director, The International Myositis Assessment and Clinical Studies Group (IMACS)
2006-2021	Founder and Director, The Myositis Genetics Consortium (MYOGEN)
2016-2018	Presenter, ACR Meet the Professor Series, Myositis and Myopathies
2017	Presenter, NIEHS Congressional Update on the Environment and Autoimmunity
2018	Scientific Reviewer, German Federal Ministry of Education and Research
2019-Present	Classification Criteria for Antisynthetase Syndrome (CLASS) Steering Committee
2020-Present	Appointed to the Scientific Advisory Board of the Autoimmune Registry (https://www.autoimmuneregistry.org/)
2020-Present	Member, IMACS Advisory Board
2021-Present	Emeritus IMACS Coordinator
2021-Present	International Myositis Society Steering Committee
2023	Scientific Research Committee Reviewer, Katholieke Universiteit Leuven, Belgium

Organization of Selected Workshops, Symposia, Conferences

- Co-organizer and moderator, Immunology Session, FASEB Meeting, Boston, MA, August 1993
- Co-organizer and moderator, Biologic Agents for Autoimmune Diseases IV, Washington, DC, March 1995
- Organizer and moderator, Drug-Associated Rheumatic Diseases, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, San Diego, CA, November 19, 1998
- Organizer and moderator, Defining the Environmental Causes for Autoimmune Diseases, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, Boston, MA, November 14, 1999
- Co-organizer and co-moderator, NIH Workshop on Basic and Clinical Research in Inflammatory Myopathy, NIAMS-sponsored meeting, Bethesda, MD, April 5-6, 2000
- Organizer and moderator, Approaches for Studying Possible Associations between Vaccinations and Rheumatic Disorders, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, Philadelphia, PA, October 20, 2000

- Co-organizer and moderator, 1st International Myositis Assessment and Clinical Studies Workshop, Defining Improvement in Adult and Juvenile Myositis, NIH Office of Rare Diseases, NIAMS, NINDS, and NIEHS funded meeting, San Francisco, CA, November 9-10, 2001
- Co-organizer, 2nd International Myositis Assessment and Clinical Studies Workshop, Developing Consensus on Outcomes and Clinical Trial Design Issues in Adult and Juvenile Myositis, NIH Office of Rare Diseases, NIAMS, NINDS, NIEHS funded meeting, New Orleans, LA, October 22-23, 2002
- Member, Workshop Planning Committee, Environmental Factors in Autoimmune Diseases, National Institute of Environmental Health Sciences, Durham, NC, February 4-5, 2003
- Co-organizer, 3rd International Myositis Assessment and Clinical Studies Workshop, Planning for Myositis Clinical Studies and the IMACS Data Repository, Orlando, FL, October 25-26, 2003
- Organizer and moderator, The ACR-EULAR International Myositis Classification Criteria Project Steering Group Workshop, Bethesda, MD, October 26, 2004
- Co-organizer and moderator, The ACR-EULAR International Myositis Classification Criteria Project Working Group Workshop, Dulles, VA, November 10-11, 2005
- Co-organizer and moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Update on Myositis Clinical Studies and the IMACS Data Repository, San Diego, CA, November 13, 2005
- Co-organizer and co-moderator, The PANLAR Myositis Consortium organizational meeting, Lima, Peru, August 21, 2006
- Co-organizer and speaker, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Update on Myositis Clinical Studies, Washington, DC, November 14, 2006
- Organizer and moderator, The International Myositis Genetics Consortium (MYOGEN) organizational meeting, Washington, DC, November 13, 2006
- Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Boston, MA, November 10, 2007
- Organizer and moderator, The International Myositis Genetics Consortium (MYOGEN) planning meeting, Boston, MA, November 9, 2007
- Co-organizer and co-moderator, The PANLAR Myositis Consortium meeting, Guatemala City, Guatemala, August 21, 2008
- Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, San Francisco, CA, October 27, 2008
- Co-moderator, The ACR Annual Meeting Session, Inflammatory Myopathies: Disease Mechanisms, Biomarkers and Treatment, San Francisco, CA, October 29, 2008
- Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Philadelphia, PA, October 17, 2009
- Co-organizer, NIEHS Symposium on the Environment and Autoimmune Diseases, Durham, NC, September 8-10, 2010

- Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Atlanta, GA, November 7, 2010
- Co-organizer and speaker, The NIEHS Expert Panel Workshop to Examine the Role of the Environment in Autoimmune Diseases, Durham, NC, September 7-8, 2010
- Co-organizer and moderator, The NIH Forum on the Microbiome and Autoimmunity, Bethesda, MD, April 24, 2014
- Co-organizer and moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Paris, France, June 9-10, 2014
- Member, Scientific Committee, First International Conference on Myositis, Stockholm, Sweden, May 8-11, 2015
- Co-Organizer, NIEHS Inflammation Faculty Workshop, Inflammation and the Environment: The Role of the Mitochondrion and Energy Metabolism, Research Triangle Park, NC, June 20-21, 2016
- Chair and Organizer of the Steering and Scientific Committees, The Second Global Conference on Myositis, GCOM 2017, Potomac, MD, May 5-8, 2017
- Member of the Scientific Committee, The Third Global Conference on Myositis, GCOM 2019, Berlin, Germany, March 27-30, 2019
- Member of the Steering and Scientific Committees, The Fourth Global Conference on Myositis, GCOM 2022, Prague, Czech Republic, March 17-30, 2022

Selected Invited Lectures

- Federal Interagency Working Group on Women's Health and the Environment Conference, DHHS, Washington, DC. Genetic and Environmental Determinants of Autoimmune Diseases. June 1998
- WHO Exploratory Meeting of Epidemiology of Occupational and Environmental Factors Associated with Autoimmunity, Bilthoven, the Netherlands. Epidemiologic Studies of Autoimmune Diseases and the Environment. May 2000
- University of Pittsburgh School of Medicine, Department of Medicine Grand Rounds, Pittsburgh, PA. Update on Clinical Presentation, Diagnosis, Pathogenesis and Management of Myositis. March 2001
- The Myositis Association of America Annual Conference, San Diego, CA. New Directions in Myositis Research. October 2001
- American College of Rheumatology Annual Meeting, San Francisco, CA. Meet the Professor session on Myositis and Myopathies. November 2001
- The International Myopain Society, Scientific Interdisciplinary Working Group Annual Meeting, Munich, Germany. Plenary session: News and Views on Inflammatory Myopathies. May 2002
- University College, 2nd International Myositis Workshop, London, UK. Approaches to Assessing Disease Activity and Damage in Myositis. May 2002
- Michigan Rheumatism Society Bi-Annual Meeting, Ann Arbor, MI. Special lecture – Inflammatory Myopathies through the Looking Glass of the Myositis-specific Autoantibodies. June 2002

The Myositis Association of America Annual Conference, Atlanta, GA. How We Diagnose Myositis; and Myositis Overlap Syndromes. September 2002

American College of Rheumatology Annual Meeting, New Orleans, LA. Meet the Professor session on myositis and myopathies, and Environmentally Associated Rheumatic Diseases Study Group Session, Approaches to Evaluating Myopathies in Patients on Lipid-lowering Agents. October 2002

Mexican Society of Rheumatology Meeting, Nuevo Leon, Mexico. Plenary talk: News and Views on Managing Polymyositis and Dermatomyositis. February 2003

NIEHS Conference on Environmental Factors in Autoimmune Disease, Durham, NC. Gene-Environment Interactions in Autoimmune Diseases. February 2003

The Royal Society of Medicine Kovacs Lectureship, London, UK. Myositis: Aetiology and Management. March 2003

The Henry Kunkel Society 11th Annual Meeting, New York, NY. Global Surface Ultraviolet Radiation Intensity Modulates the Clinical and Immunologic Expression of Autoimmune Muscle Disease. April 2003

Frontiers of Rheumatology - 21st Annual Carl M. Pearson Memorial Symposium, Huntington Beach, CA. Differential Diagnosis of Muscle Disease: How Useful Are Genetic Markers, Myositis Antibodies and Imaging Studies? and Optimizing the Benefit/Risk Ratio in the Management of Inflammatory Myopathies. May 2003

The UK Myositis Support Group Annual Meeting, Birmingham, UK. Genetic and Environmental Risk Factors for Myopathies. June 2003

NIEHS Public Interest Liaison Group Meeting, New York, NY. Autoimmune Disorders and Environmental Factors. September 2003

The Myositis Association Annual Conference, Houston, TX. Translational Research on Myositis, from Bench to Bedside. October 2003

American College of Rheumatology Annual Meeting, Orlando, FL. Meet the Expert Session on Myositis and Myopathies. October 2003

Clinical Immunology Society (CIS) Spring School in Systemic Autoimmune Diseases Meeting, Santa Fe, NM. Environmental and Genetic Aspects of Autoimmune Diseases: The Case for Elemental Disorders. March 2004

Myopain 2004, Annual Meeting of the International Myopain Society, Munich, Germany. Plenary Lecture: Deconstructing Myositis – From Bedside to Bench and Back Again. July 2004

The Myositis Association Annual Conference, Las Vegas, NV. Talking with Your Doctor about Myositis, and Myositis 101: What Patients Need to Know, and Myositis Research Update. August 2004

NIAID Eosinophilia Myalgia Syndrome (EMS) Conference, Bethesda, MD. Genetic Risk and Protective Factors for EMS. October 2004

NIEHS Division of Intramural Research Retreat, New Bern, NC. Mini Symposium on Environmental Aspects of Immune-Mediated Diseases. October 2004

Canadian Rheumatology Association National Meeting, Mont Tremblant, Quebec, Canada. The Dunlop-Dotteridge Plenary Lecture: Close Encounters with the Myositis Syndromes. March 2005

- The Annual European League of Associations for Rheumatism (EULAR) Congress of Rheumatology, Vienna, Austria. Environmental Factors in Muscle Weakness. June 2005
- NIEHS Translation of Environmental Health Sciences Retreat, Chapel Hill, NC. Intramural Clinical Research and Approaches to Enhancing Translational Studies. June 2005
- XIV Congress of the Pan-American League of Associations for Rheumatology (PANLAR) Lima, Peru. Defining Risk Factors and Pathogenesis in Inflammatory Muscle Disease. August 2006
- New York Rheumatology Board Review Course, New York, NY. Update on Inflammatory and Other Myopathies. September 2006
- American College of Rheumatology Annual Meeting, Washington, DC. ACR Clinical Symposium, Developments in Myositis Response Criteria. November 2006
- The Myositis Association Medical Advisory Board Annual Meeting, Washington, DC. Research Progress and Opportunities in Polymyositis and Dermatomyositis. January 2007
- 6th International Rheumatology Symposium, Yokohama, Japan. Adventures in Inflammatory Muscle Diseases. April 2007
- Puerto Rican Rheumatologist's Association International Meeting, San Juan, Puerto Rico. Dissecting Genotype-Phenotype Interactions in Myositis. May 2007
- MYOPAIN 2007, Washington, DC. Disorders of Muscle Inflammation – Pathogenic Insights from Environmental and Epidemiologic Studies. August 2007
- New York Rheumatology Board Review Course, New York, NY. Update on Inflammatory and Other Myopathies. September 2007
- Cure Juvenile Myositis Meeting, Washington, DC. Genetics of Myositis – Current Status and New Opportunities. October 2007
- The 10th International Workshop on Autoantibodies and Autoimmunity, Guadalajara, Mexico. Environmental Aspects of Autoimmunity. March 2008
- The Hospital for Special Surgery Grand Rounds, New York, NY. Close Encounters with the Myositis Syndromes. April 2008
- Saint Louis University Medical Center Grand Rounds, St. Louis, MO. Deconstructing Myositis – What We Know, What We Think We Know and What We Need to Know. May 2008
- The Collaborative on Health and the Environment Online Presentation and Discussion Series. Environmental Factors in the Pathogenesis of Systemic Autoimmune Diseases. July 2008
- The XV PANLAR Congress, Guatemala City, Guatemala. Plenary Session, New Insights into the Pathogenesis and Management of Myositis. August 2008
- NIEHS Public Interest Liaison Group Meeting, Washington, DC. NIEHS Translational Research in the Environment and Autoimmune Diseases. September 2008
- New York Rheumatology Board Review Course, New York, NY. Update on Inflammatory and Other Myopathies. September 2008

The 15th Pediatric Rheumatology European Society Congress, London, UK. Dissecting Genotype-Phenotype Interactions in the Pathogenesis of Adult and Juvenile Myositis. September, 2008

The Myositis Association Annual Meeting, Denver, CO. The Environment and Autoimmune Diseases – Where We Stand in 2008; and Myositis Research Highlights – What Have We Learned in the Last 15 Years. September 2008

University of North Carolina Rheumatology Grand Rounds, Chapel Hill, NC. Myositis Pearls, Myths and Realities. November 2008

AUTOCURE 2008 Meeting, Prague, Czech Republic. Genetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies. December 2008

Washington Hospital Center, Dept. of Medicine Grand Rounds, Washington, DC. Unweaving the Tapestry of Myositis One Patient at a Time. January 2009

The First Myositis Association Research Symposium, Baltimore, MD. The Genetics of Myositis – the Search for Elemental Disorders. January 2009

New York Rheumatology Board Review Course, New York, NY. Update on Inflammatory and Other Myopathies. October 2009

NIH Medical-Surgical Training Program, Bethesda, MD. Myositis 101 – The Essential Information You Need to Know to Care for Patients with Autoimmune Muscle Diseases. November 2009

NIH Clinical Center Grand Rounds, Bethesda, MD. Phenotypes as Clues to Deciphering the Pathogenesis and Treatment of Myositis. February 2010

Autoimmune Diseases Summit: The Global State of Autoimmunity Today, Baltimore, MD. The Escalating Problem of Autoimmune Diseases: Investigating the Epidemic Increase in Incidence and Environmental Associations. March 2010

University of Alabama School of Medicine Grand Rounds, Birmingham, AL. New Developments in the Diagnosis, Pathogenesis and Management of Myositis. June 2010

NIH Summer Intern Training Program Speaker Series, Bethesda, MD, Why the Environment is Critical to Understanding Autoimmune Diseases, July 2010

Frontiers of Rheumatology, Mexico City, Mexico. Close Encounters with the Myositis Syndromes. September 2010

Virginia Society of Rheumatology Annual Meeting, Virginia Beach, VA. Myositis Pathogenesis, Assessment and Treatment. October 2010

NIH Office of Research on Women's Health Seminar Series, Bethesda, MD. Environmental Aspects of Autoimmune Diseases. October 2010

New York Rheumatology Board Review Course, New York, NY. Review of Inflammatory and Other Myopathies. October 2010

American College of Rheumatology Annual Meeting, Atlanta, GA. Myositis 2010, A to Z. November 2010

Joint Canadian-Mexican Congress of Rheumatology, Cancun, Mexico. Update on Therapies for Myositis. February 2011

Advances in Targeted Therapies Meeting, Dubrovnik, Croatia. New Approaches to Understanding the Pathogenesis, Assessment and Treatment of Myositis. April 2011

- NIH Neuromuscular Interest Group, Bethesda, MD. Close Encounters with the Myositis Syndromes. May 2011
- DC Rheumatism Society Fellows Forum in Washington, DC. Plenary talk, Myositis 2011: Past, Present and Future. June 2011
- The Hospital for Special Surgery Grand Rounds, New York, NY. Myositis Revisited: New Developments in Pathogenesis and Therapy. July 2011
- New York Rheumatology Board Review Course, New York, NY. Update on Inflammatory and Other Myopathies. September 2011
- NIH ORD Cicatricial Alopecia Research Symposium, Bethesda, MD. Keynote Presentation - UV Radiation and Autoimmune Disease in Women. October 2011
- American College of Rheumatology Annual Meeting, Chicago, IL. The Environment and Autoimmune Diseases – Where We Stand in 2011; Epidemiology of the Antisynthetase Syndrome; Career Opportunities for Rheumatologists in Government; IMACS Scientific Committee - Proposals on Project and Manuscript Reviews; Genome-Wide Association Study of Dermatomyositis Reveals Shared Genetic Risk Factors with Other Autoimmune Diseases. November 2011
- National Advisory Environmental Health Sciences Council Meeting, NIEHS, Research Triangle Park, NC. The Environment, Genetics and Age – The Ménage à Trios of Autoimmunity. February 2012
- South Atlantic National Research Conference, Raleigh, NC. The Role of Patient Support Groups in Community Research. March 2012
- American Association of Immunology, National Meeting, NIEHS Symposium, Boston, MA. Environmental Risk Factors for Autoimmune Diseases. April 2012
- Medical College of Wisconsin Grand Rounds, Milwaukee, WI. The Importance of Phenotypes in Deciphering the Clinical Presentations, Pathogenesis and Treatment of Myositis. April 2012
- NIEHS Partners Meeting, Research Triangle Park, NC. Update on the Environment and Autoimmune Diseases – What We Know and What We Need to Know. June 2012
- Society for Women's Health Research Sponsored Roundtable, Washington, DC. Sex- and Gender-Specific Environmental Exposures and Mechanisms in Autoimmune Disorders. October 2012
- Cure Juvenile Myositis Medical Conference, Johns Hopkins Hospital, Baltimore, MD. New Developments in Understanding the Genetics of Myositis. October 2012
- American College of Rheumatology Annual Meeting, Washington, DC. Update on the International Myositis Assessment and Clinical Studies Group. November 2012
- 13th International Workshop on Scleroderma Research, Boston, MA. Identifying Environmental Factors in Autoimmune Disease. August 2013
- 5th International Myositis Workshop, Tokyo, Japan. Keynote speaker: International Research Initiatives in Inflammatory Muscle Disease; and Opportunities for Research at the NIH. September 2013

- The Myositis Association Annual Meeting, Louisville, KY. Major Advances in Myositis over Two Decades; Myositis – Clues from the Environment; and MYOVISION – the First National Registry for Myositis. October 2013
- American College of Rheumatology Annual Meeting, San Diego, CA. Controversies in the Criteria for Myositis; and Update on the International Myositis Assessment and Clinical Studies Group Scientific Committee. October 2013
- NIH Translational Interest Group, Bethesda, MD. Autoimmune Disease Phenotypes: Touchstones for Identifying Genetic and Environmental Risk Factors. January 2014
- Gordon Conference, Ventura, CA. Discussion leader: Free Radical Metabolites in the Initiation of Autoimmunity. February 2014
- Advances in Targeted Therapies Symposium, Athens, Greece. Is there Hope for Finding New Targets to Treat Myositis? March 2014
- NIH Process of Discovery Lecture Series, Bethesda, MD. Adventures in Autoimmunity – A Personal Journey. April 2014
- Grand Rounds, Dept. Rheumatology, Georgetown University Hospital, Washington, DC. Environmental Aspects of Autoimmune Diseases in 2014. May 2014
- 2nd International Myositis Genetics Conference, Manchester UK. Genome-Wide Association Studies in Myositis Define the Different Members of HLA 8.1 Haplotype as Primary Genetic Risk Factors for Different Phenotypes. May 2014
- International Myositis Assessment and Clinical Studies Group (IMACS) Outcomes Workshop, Paris, France. Defining New Consensus Outcomes for Adult and Juvenile Myositis. June 2014
- NIH Intramural Population Science Consortium, Rockville, MD. NIEHS Clinical Resources, Databases and Repositories. October 2014
- American College of Rheumatology Annual Meeting, Boston, MA, Cancer and Myositis: Whom Should We Screen for Malignancy? and History of Classification Criteria for the Idiopathic Inflammatory Myopathies. November 2014
- NIEHS Emerging Biomarkers of Inflammation, Research Triangle Park, NC. Novel Biomarkers of Myositis. February 2015
- Grand Rounds, Washington VA Medical Center, Washington, DC. The Environment and Autoimmunity: A New Synthesis. March 2015
- American Autoimmune Related Diseases Association State of Autoimmune Disease: A National Summit meeting, Washington, DC. Update on Environmental Risk Factors for Autoimmune Phenotypes. April 2015
- 11th International Lupus Conference, Vienna, Austria. Primary Myositis and SLE-Related Myositis: Similarities and Differences, and Meet the Professor session on Myositis. September 2015
- American College of Rheumatology Annual Meeting, San Francisco, CA. Moderator, New Adult and Juvenile Myositis Response Criteria. November 2015

- NIEHS Environmental Autoimmunity Meeting, Research Triangle Park, NC. Insights into Environmental Factors in Autoimmunity and Systemic Autoimmune Diseases: A Rheumatologist's Perspective. December 2015
- Intracity Conference, Toronto, Canada. Genes, the Environment and Age – The Ménage à Trois of Myositis; and Murray St. Clinical Rounds - Close Encounters with the Myositis Syndromes. March 2016
- International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Washington, DC. Overview and Invitation to the Global Conference on Myositis 2017 and A Memorial to Mark Gourley, M.D. November 2016
- American College of Rheumatology Annual Meeting, Washington, DC. Meet the Professor sessions on Muscle Disease; and How to Approach Cancer Evaluation in Myositis. November 2016
- Keynote Speech, Annual Meeting of the Japanese Society for Hygiene, Miyazaki, Japan. Environmental Factors in Autoimmune Diseases - What We Know in 2017. March 2017
- Medical Grand Rounds, NYU Langone Medical Center, New York, NY. New Developments in the Idiopathic Inflammatory Myopathies. May 2017
- The Second Global Conference on Myositis, Potomac, MD. Moderator and Presenter, Environmental Risk Factors for Adult and Juvenile Myositis from US Registries. May 2017
- Medical Grand Rounds, Georgetown University Hospital, Washington, DC. Environmental Aspects of Autoimmunity. June 2017
- Congressional Briefing, Washington, DC, Environmental Agents that Cause Autoimmune Diseases. October 2017
- American College of Rheumatology Annual Meeting, San Diego, CA. Meet the Professor sessions on Muscle Disease. November 2017
- International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, San Diego, CA. Overview of the Global Conference on Myositis 2017. November 2017
- CRB, NIEHS Seminar, Research Triangle Park, NC. Autoimmunity in America – Who, What, Where, When and Why? March 2018
- NIH Clinical Center Grand Rounds, Bethesda, MD, Understanding Risk Factors and Mechanisms in Myositis. June 2018
- American College of Rheumatology Annual Meeting, Chicago, IL. Meet the Professor sessions on Muscle Disease, and Emerging Autoantibodies in the Diagnosis and Management of Myositis Patients with ILD. October 2018
- International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Chicago, IL. A 25-Year History of Myositis Support and The Myositis Association. October 2018
- University of North Carolina Rheumatology Grand Rounds – Close Encounters with the Myositis Syndromes, Chapel Hill, NC, March 2019
- International Myositis Assessment and Clinical Studies Group (IMACS) Annual Meeting, Atlanta, GA. Reflections on the History of IMACS, and The Great Debate – Does Polymyositis Exist? November 2019

- Mt. Sinai Hospital, Rheumatology Grand Rounds, New York, NY (virtual). Current Understanding of Risk Factors, Pathogeneses, Phenotypes and Treatments for Myositis, November 2020
- Cancer Epidemiology and Genetics Rounds, NCI, NIH, Bethesda, MD (virtual). Malignancy in Myositis: Evidence, Risk Factors and How Hard Should I Look? March 2021
- American College of Rheumatology Annual Meeting (virtual). Climate Change, Pollution and Rheumatic Disease. November 2021
- 2nd Yale Rheumatology International State of the Art Symposium (virtual). Increasing Autoimmunity and Autoimmune Diseases: Who, What, Where, When and Why? May 2022
- Festschrift for Professor David Isenberg - Past, present and future of autoimmune rheumatology diseases. Royal Society of Medicine, London, UK. September 2022
- Autoimmune Association Community Summit, Virtual meeting. Increasing Autoimmunity and Autoimmune Diseases: Causes and Needed Actions. October 2022
- American College of Rheumatology Annual Meeting (virtual). Myositis: Meet the Master Community Hub. November 2022
- Duke University Climate Change and Immune Health Symposium, Durham, NC. The Increasing Prevalence of Autoimmunity and Autoimmune Diseases: The Roles of Environmental Risk Factors and Climate Change. June 2023

Mentoring

Directed research projects and mentored dozens of undergraduate students, PhD thesis candidates, graduate students, medical students, postdoctoral fellows, clinical research fellows, visiting scientists, guest workers, and summer students at the Food and Drug Administration and National Institutes of Health (1983-present).

Selected Recent Trainees:

- Alyssa D'Oyen, Post-bac Fellow, NIEHS, NIH, Durham, NC # ##
- Lu Gan, M.D., Ph.D., Postdoctoral Fellow, NIEHS, NIH, Bethesda, MD #
- Sepehr Mesdaghinia, M.D., Rheumatology Fellow, Georgetown Univ. Med. Ctr., Washington DC ##
- Abdullah Faiq, Medical Student, Howard University, Washington DC ##
- Zhouyan Li, Medical Student, Vanderbilt University School of Medicine, Nashville, TN #
- Kathleen Gorman, Medical Student, University of Maryland School of Medicine, Baltimore, MD #
- Mona Shah, Ph.D. (Ph.D. thesis, 2012 in Epidemiology, George Washington University), Program Officer, Robert Wood Johnson Foundation, Princeton NJ # ##

Leora Vegosen, Ph.D., M.H.S., Editor for American Journal Experts, Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD #

Rita Volochayev, C.R.N.P., C.P.M.N., Ph.D. (Ph.D. thesis, 2011 in Epidemiology, Walden University), Family Nurse Practitioner, NINDS, NIH, Bethesda, MD #

James Yeh, Medical Student, Duke University, Durham, NC

Adrienne Yip, Medical Student, University of Maryland School of Medicine, Baltimore, MD #

women, ## underserved minority trainee

Selected Past Trainees:

Elham Bayat, M.D., Assistant Professor, Department of Neurology, Director of the ALS Multidisciplinary Clinic, George Washington University, Washington, DC

Catherine A. Bingham, M.D., Assistant Professor, Department of Pediatric Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA

Lauren Komarow, Ph.D., Biostatistician III, Statistical and Data Analysis Center, Harvard School of Public Health, Boston MA

Gulnara Mamyrova, M.D., Ph.D., Research Assistant Professor, Department of Medicine, Division of Rheumatology, The George Washington University, Washington, DC.

Winona Mesiona-Lee, M.D., Associate Professor, Department of Pediatrics, John A. Burns School of Medicine, Honolulu, HI

Wells Messersmith, M.D., FACP, Professor of Surgery, Director, GI Medical Oncology Program, Co-Leader, Developmental Therapeutics Program, Co-Head, Division of Medical Oncology, University of Colorado Cancer Center, University of Colorado School of Medicine, Denver, CO

Terrance O'Hanlon, Ph.D., Senior Research Assistant and Laboratory Manager, Environmental Autoimmunity Group, Clinical Research Program, NIEHS, NIH, Bethesda, MD (retired)

Satoshi Okada, M.D., Ph.D., Senior Assistant Professor, Department of Neurology, Ichikawa General Hospital, Tokyo Dental College, Tokyo, Japan

Lisa Rider, M.D., Head and Senior Clinician, Environmental Autoimmunity Group, Clinical Research Program, NIEHS, NIH, Bethesda, MD

Kakali Sarkar, Ph.D., Biologist, Environmental Autoimmunity Group, Clinical Research Program, NIEHS, NIH, Bethesda, MD

Adam Schiffenbauer, M.D., Deputy Head and Staff Clinician, Environmental Autoimmunity Group, Clinical Research Program, NIEHS, NIH, Bethesda, MD

Ejaz Shamim, M.D., M.S., Director of Neurology and Research, Kaiser Permanente Mid-Atlantic Permanente Medical Group, Rockville, MD

Funding Support Outside of NIEHS

1992 and 1997 Principal Investigator, FDA Office of Woman's Health grant recipient for risk factors related to silicone related autoimmunity (\$150,000 each award) (25% effort)

- 2001 - 2002 Co-Principal Investigator, NIH Office of Rare Diseases and NINDS funding for 2 workshops on Outcome Assessment and Clinical Trial Design in the Idiopathic Inflammatory Myopathies (\$25,000 each year) (10% effort)
- 2006 – 2009 Principal Investigator, Inter-agency agreement, NIAMS, Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathies (NIEHS as enrollment site, \$515,586) (25% effort)
- 2005 – 2009 American College of Rheumatology, Development of Outcome Measures for Myositis (\$15,000 to support database development and management) (10% effort)
- 2011 – 2021 Principal Investigator, “Potential Environmental Triggers of Myositis”, The Myositis Association, from a cooperative agreement with the Department of Defense (W81XWH-11-1-0730) (\$596,575) (10% effort)
- 2012 – 2016 Co-Principal Investigator, American College of Rheumatology-European League Against Rheumatism grant, “Development of Response Criteria for Adult and Juvenile Myositis” (\$130,000) (10% effort)
- 2013 – 2014 Funding for ACR-EULAR Consensus Conference for the Development of Response Criteria for Adult and Juvenile Myositis (\$60,000 from NIH Office of Rare Diseases, NIEHS, NIAMS, Cure JM Foundation, UK Myositis Support Group and The Myositis Association) (10% effort)
- 2017 – 2022 Associate Investigator, An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated with Juvenile and Adult Dermatomyositis (\$1,559,120, CRADA with Hope Pharmaceuticals, EHS-CTCR-1) (10% effort)

Bibliography

Primary Publications in Peer-Reviewed Journals

1. Ilan J, Pierce DR, **Miller FW**. Influence of 9-beta-D-arabinofuranosyladenine on total protein synthesis and on differential gene expression of unique proteins in the rodent malarial parasite *Plasmodium berghei*. *Proc Natl Acad Sci U S A*. 1977;74(8):3386-90. doi: 10.1073/pnas.74.8.3386. PMID: 333437; PMCID: PMC431572.
2. **Miller FW**, Ilan J. The ribosomes of *Plasmodium berghei*: isolation and ribosomal ribonucleic acid analysis. *Parasitology*. 1978;77(3):345-65. doi: 10.1017/s0031182000050307. PMID: 372893.
3. Chawla RK, **Miller FW**, Lawson DH, Nixon DW. Urinary cancer-related protein EDC1 and serum inter-alpha trypsin inhibitor in breast cancer. *Tumour Biol*. 1984;5(6):351-63. doi. PMID: 6085600.

4. Chawla RK, Rausch DJ, **Miller FW**, Vogler WR, Lawson DH. Abnormal profile of serum proteinase inhibitors in cancer patients. *Cancer Res.* 1984;44(6):2718-23. doi. PMID: 6722803.
5. **Miller FW**, Ilan J. Evidence for major differences in ribosomal subunit proteins from *Plasmodium berghei* and rat liver. *Molecular and biochemical parasitology.* 1984;12(3):249-60. doi: 10.1016/0166-6851(84)90082-3. PMID: 6384776.
6. **Miller FW**, Santoro TJ. Nifedipine in the treatment of migraine headache and amaurosis fugax in patients with systemic lupus erythematosus. *N Engl J Med.* 1984;311(14):921. doi: 10.1056/NEJM198410043111416. PMID: 6472409.
7. Biswas T, **Miller FW**, Twitty SA, Plotz PH. An efficient method for enrichment of histidyl-tRNA synthetase (Jo-1 antigen) from HeLa cells. *J Immunol Methods.* 1987;98(2):235-41. doi: 10.1016/0022-1759(87)90010-x. PMID: 3494783.
8. Biswas T, **Miller FW**, Takagaki Y, Plotz PH. An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. *J Immunol Methods.* 1987;98(2):243-8. doi: .1016/0022-1759(87)90011-1. PMID: 3494784.
9. **Miller FW**, Love LA, Biswas T, McClintock PR, Notkins AL, Plotz PH. Viral and host genetic factors influence encephalomyocarditis virus- induced polymyositis in adult mice. *Arthritis Rheum.* 1987;30(5):549-56. doi: 10.1002/art.1780300509. PMID: 3036171.
10. **Miller FW**, Love LA. Prevention of predictable Raynaud's phenomenon by sublingual nifedipine. *N Engl J Med.* 1987;317(23):1476. doi. PMID: 3683482.
11. **Miller FW**, Santoro TJ, Papadopoulos NM. Idiopathic anasarca associated with oligoclonal gammopathy in systemic lupus erythematosus. *J Rheumatol.* 1987;14(4):842-3. doi. PMID: 3118021.
12. **Miller FW**, Moore GF, Weintraub BD, Steinberg AD. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. *Arthritis Rheum.* 1987;30(10):1124-31. doi: 10.1002/art.1780301006. PMID: 3675658.
13. Biswas T, **Miller FW**, Plotz PH. Stimulation and partial stabilization of human histidyl-tRNA synthetase by hemoglobin. *FEBS letters.* 1988;229(1):203-5. doi: 10.1016/0014-5793(88)80827-5. PMID: 3345836.

14. Allaway GP, Srinivasappa J, **Miller FW**, Prabhakar BS, Notkins AL. Spontaneously proliferating human B lymphocytes make autoantibodies. *J Infect Dis.* 1988;157(5):968-72. doi: 10.1093/infdis/157.5.968. PMID: 2834468.
15. Cronin ME, Love LA, **Miller FW**, McClintock PR, Plotz PH. The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization. *JExpMed.* 1988;168(5):1639-48. doi: 10.1084/jem.168.5.1639. PMID: 2846742; PMCID: PMC2189103.
16. Cronin ME, Plotz PH, **Miller FW**. Abnormalities of the immune system in the idiopathic inflammatory myopathies. *In Vivo.* 1988;2(1):25-9. doi. PMID: 2979812.
17. Cronin ME, **Miller FW**, Hicks JE, Dalakas M, Plotz PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. *J Rheumatol.* 1989;16(9):1225-8. doi. PMID: 2681763.
18. Kalovidouris AE, **Miller FW**, Lawley TJ. Polymyositis/dermatomyositis associated with dermatitis herpetiformis. *Arthritis Rheum.* 1989;32(9):1179-81. doi: 10.1002/anr.1780320920. PMID: 2789048.
19. Plotz PH, Dalakas M, Leff RL, Love LA, **Miller FW**, Cronin ME. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. *AnnInternMed.* 1989;111(2):143-57. doi: 10.7326/0003-4819-111-2-143. PMID: 2662848.
20. Ramsden DA, Chen J, **Miller FW**, Misener V, Bernstein RM, Siminovitch KA, Tsui FW. Epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase. Analysis of the myositis-associated anti-Jo-1 autoimmune response. *J Immunol.* 1989;143(7):2267-72. doi. PMID: 2476503.
21. Recker DP, Minor JR, **Miller FW**. Successful prevention of an anaphylactoid reaction to high-dose methotrexate. *DICP.* 1989;23(12):1032. doi: 10.1177/106002808902301218. PMID: 2603443.
22. **Miller FW**, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotypic stability, and isotype restriction of anti-Jo-1 autoantibodies. *J Clin Invest.* 1990;85(2):468-75. Epub 1990/02/01. doi: 10.1172/jci114461. PMID: 1688885; PMCID: PMC296447.

23. **Miller FW**, Love LA, Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. *Clin Exp Immunol.* 1990;81(3):373-9. doi: 10.1111/j.1365-2249.1990.tb05341.x. PMID: 2168821; PMCID: PMC1534997.
24. Targoff IN, Johnson AE, **Miller FW**. Antibody to signal recognition particle in polymyositis. *Arthritis Rheum.* 1990;33(9):1361-70. doi: 10.1002/art.1780330908. PMID: 2403400.
25. **Miller FW**, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. *Proc Natl Acad Sci U S A.* 1990;87(24):9933-7. Epub 1990/12/01. doi: 10.1073/pnas.87.24.9933. PMID: 1702223; PMCID: PMC55288.
26. Baker JR, Jr., **Miller FW**, Steinberg AD, Burman KD. Thyroid stimulating and thyrotrophin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. *Thyroid.* 1991;1(3):229-34. doi: 10.1089/thy.1991.1.229. PMID: 1688101.
27. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, **Miller FW**. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. *Medicine.* 1991;70(6):360-74. doi: 10.1097/00005792-199111000-00002. PMID: 1659647.
28. Fraser DD, Frank JA, Dalakas M, **Miller FW**, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. *J Rheumatol.* 1991;18(11):1693-700. doi. PMID: 1787491.
29. Leff RL, Burgess SH, **Miller FW**, Love LA, Targoff IN, Dalakas MC, Joffe MM, Plotz PH. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. *Arthritis Rheum.* 1991;34(11):1391-6. doi: 10.1002/art.1780341108. PMID: 1953817.
30. **Miller FW**, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. *N Engl J Med.* 1992;326(21):1380-4. doi: 10.1056/nejm199205213262102. PMID: 1472183.
31. Leff RL, Love LA, **Miller FW**, Greenberg SJ, Klein EA, Dalakas MC, Plotz PH. Viruses in idiopathic inflammatory myopathies: absence of candidate

- viral genomes in muscle. *Lancet*. 1992;339(8803):1192-5. doi: 10.1016/0140-6736(92)91134-t. PMID: 1349938.
32. Fraser DD, Kong LI, **Miller FW**. Molecular detection of persistent *Borrelia burgdorferi* in a man with dermatomyositis. *Clin Exp Rheumatol*. 1992;10(4):387-90. doi. PMID: 1395222.
 33. Targoff IN, Trieu EP, Plotz PH, **Miller FW**. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. *Arthritis Rheum*. 1992;35(7):821-30. doi: 10.1002/art.1780350718. PMID: 1622421.
 34. Raben N, Sherman J, **Miller F**, Mena H, Plotz P. A 5' splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). *J Biol Chem*. 1993;268(7):4963-7. doi. PMID: 8444874.
 35. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, **Miller FW**. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. *Am J Med*. 1993;94(4):379-87. doi: 10.1016/0002-9343(93)90148-i. PMID: 8386437.
 36. Targoff IN, Trieu EP, **Miller FW**. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. *J Clin Invest*. 1993;91(6):2556-64. doi: 10.1172/JCI116493. PMID: 8514867; PMCID: PMC443318.
 37. Love LA, **Miller FW**. Noninfectious environmental agents associated with myopathies. *Curr Opin Rheumatol*. 1993;5(6):712-8. doi: 10.1097/00002281-199305060-00004. PMID: 8117532.
 38. Leff RL, **Miller FW**, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. *Medicine*. 1993;72(4):225-35. doi: 10.1097/00005792-199307000-00002. PMID: 8393509.
 39. Hicks JE, **Miller F**, Plotz P, Chen TH, Gerber L. Isometric exercise increases strength and does not produce sustained creatinine phosphokinase increases in a patient with polymyositis. *J Rheumatol*. 1993;20(8):1399-401. doi. PMID: 8230026.
 40. **Miller FW**. Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. *JAMA*. 1993;270(15):1846-9. doi: 10.1001/jama.270.15.1846. PMID: 8411528.

41. O'Hanlon TP, Dalakas MC, Plotz PH, **Miller FW**. Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *J Immunol* (Baltimore, Md : 1950). 1994;152(5):2569-76. doi. PMID: 8133064.
42. Rider LG, **Miller FW**. New perspectives on the idiopathic inflammatory myopathies of childhood. *Curr Opin Rheumatol*. 1994;6(6):575-82. doi: 10.1097/00002281-199411000-00005. PMID: 7865376.
43. O'Hanlon TP, Dalakas MC, Plotz PH, **Miller FW**. The alpha beta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. *J Autoimmun*. 1994;7(3):321-33. Epub 1994/06/01. doi: 10.1006/jaut.1994.1023. PMID: 7916906.
44. Potter M, Morrison S, Wiener F, Zhang XK, **Miller FW**. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. *J Natl Cancer Inst*. 1994;86(14):1058-65. doi: 10.1093/jnci/86.14.1058. PMID: 8021954.
45. Rider LG, **Miller FW**, Targoff IN, Sherry DD, Samayoa E, Lindahl M, Wener MH, Pachman LM, Plotz PH. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. *Arthritis Rheum*. 1994;37(10):1534-8. doi: 10.1002/art.1780371019. PMID: 7945480.
46. Boerkoel CF, Exelbert R, Nicastrì C, Nichols RC, **Miller FW**, Plotz PH, Raben N. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. *Am J Hum Genet*. 1995;56(4):887-97. doi. PMID: 7717400; PMCID: PMC1801206.
47. O'Hanlon TP, Raben N, **Miller FW**. A novel gene oriented in a head-to-head configuration with the human histidyl-tRNA synthetase (HRS) gene encodes an mRNA that predicts a polypeptide homologous to HRS. *Biochem Biophys Res Commun*. 1995;210(2):556-66. doi: 10.1006/bbrc.1995.1696. PMID: 7755634.
48. O'Hanlon TP, Messersmith WA, Dalakas MC, Plotz PH, **Miller FW**. Gamma delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *Clin Exp Immunol*. 1995;100(3):519-28. Epub 1995/06/01. doi: 10.1111/j.1365-2249.1995.tb03732.x. PMID: 7774065; PMCID: PMC1534468.
49. O'Hanlon TP, Dalakas MC, Plotz PH, **Miller FW**. The alpha beta T-cell receptor repertoire in idiopathic inflammatory myopathies: distinct patterns of gene expression by muscle-infiltrating lymphocytes in different clinical

- and serologic groups. *Ann N Y Acad Sci.* 1995;756:410-3. doi: 10.1111/j.1749-6632.1995.tb44548.x. PMID: 7645860.
50. Rider LG, **Miller FW**. Laboratory evaluation of the inflammatory myopathies. *Clin Diagn Lab Immunol.* 1995;2(1):1-9. doi: 10.1128/cdli.2.1.1-9.1995. PMID: 7719899; PMCID: PMC170091.
 51. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, **Miller FW**. Myositis: Immunologic contributions to understanding cause, pathogenesis and therapy. *Annals Internal Medicine.* 1995;122(9):715-24. doi: 10.7326/0003-4819-122-9-199505010-00010. PMID: 7702234.
 52. O'Hanlon TP, **Miller FW**. T cell-mediated immune mechanisms in myositis. *Curr Opin Rheumatol.* 1995;7(6):503-9. doi: 10.1097/00002281-199511000-00007. PMID: 8579970.
 53. Potter M, Morrison S, **Miller F**. Induction of plasmacytomas in genetically susceptible mice with silicone gels. *Curr Top Microbiol Immunol.* 1995;194:83-91. doi: 10.1007/978-3-642-79275-5_11. PMID: 7895524.
 54. O'Hanlon TP, Okada S, Love LA, Dick G, Young VL, **Miller FW**. Immunohistopathology and T cell receptor gene expression in capsules surrounding silicone breast implants. *Curr Top Microbiol Immunol.* 1996;210:237-42. doi: 10.1007/978-3-642-85226-8_23. PMID: 8565561.
 55. Rivest C, **Miller FW**, Love LA, Turgeon PP, Blier C, Senécal JL. Focal myositis presenting as pseudothrombophlebitis of the neck in a patient with mixed connective tissue disease. *Arthritis Rheum.* 1996;39(7):1254-8. doi: 10.1002/art.1780390728. PMID: 8670340.
 56. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, **Miller FW**, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M, Jablonska S. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. *Arthritis Rheum.* 1997;40(7):1257-66. doi: 10.1002/1529-0131(199707)40:7<1257::AID-ART10>3.0.CO;2-R. PMID: 9214426.
 57. Targoff IN, **Miller FW**, Medsger TA, Jr., Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. *Curr Opin Rheumatol.* 1997;9(6):527-35. doi: 10.1097/00002281-199711000-00008. PMID: 9375282.
 58. Rider LG, **Miller FW**. Classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheum Dis Clin North Am.* 1997;23(3):619-55. doi: 10.1016/s0889-857x(05)70350-1. PMID: 9287380.

59. Rider LG, Feldman BM, Perez MD, Rennebohm RM, Lindsley CB, Zemel LS, Wallace CA, Ballinger SH, Bowyer SL, Reed AM, Passo MH, Katona IM, **Miller FW**, Lachenbruch PA. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *Arthritis Rheum.* 1997;40(11):1976-83. doi: 10.1002/art.1780401109. PMID: 9365086.
60. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, **Miller FW**. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. *Arthritis Rheum.* 1998;41(3):392-9. doi: 10.1002/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X. PMID: 9506565.
61. Ginn LR, Lin JP, Plotz PH, Bale SJ, Wilder RL, Mbauya A, **Miller FW**. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. *Arthritis Rheum.* 1998;41(3):400-5. Epub 1998/03/20. doi: 10.1002/1529-0131(199803)41:3<400::AID-ART4>3.0.CO;2-5. PMID: 9506566.
62. Rider LG, Gurley RC, Pandey JP, Garcia de la Torre I, Kalovidouris AE, O'Hanlon TP, Love LA, Hennekam RC, Baumbach LL, Neville HE, Garcia CA, Klingman J, Gibbs M, Weisman MH, Targoff IN, **Miller FW**. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheum.* 1998;41(4):710-9. doi: 10.1002/1529-0131(199804)41:4<710::AID-ART19>3.0.CO;2-K. PMID: 9550481.
63. Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, **Miller FW**, White PH, Malley JD, Rider LG. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. *Radiology.* 1998;209(1):191-6. doi: 10.1148/radiology.209.1.9769831. PMID: 9769831.
64. Rider LG, Shamim E, Okada S, Pandey JP, Targoff IN, O'Hanlon TP, Kim HA, Lim YS, Han H, Song YW, **Miller FW**. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. *Arthritis Rheum.* 1999;42(6):1285-90. doi: 10.1002/1529-0131(199906)42:6<1285::AID-ANR28>3.0.CO;2-1. PMID: 10366124.
65. Abbondanzo SL, Young VL, Wei MQ, **Miller FW**. Silicone gel-filled breast and testicular implant capsules: a histologic and immunophenotypic study. *Mod Pathol.* 1999;12(7):706-13. doi. PMID: 10430275.

66. Centeno JA, Mullick FG, Panos RG, **Miller FW**, Valenzuela-Espinoza A. Laser-Raman microprobe identification of inclusions in capsules associated with silicone gel breast implants. *Mod Pathol.* 1999;12(7):714-21. doi. PMID: 10430276.
67. Laskin BL, Choyke P, Keenan GF, **Miller FW**, Rider LG. Novel gastrointestinal tract manifestations in juvenile dermatomyositis. *J Pediatr.* 1999;135(3):371-4. doi: 10.1016/s0022-3476(99)70137-x. PMID: 10484806.
68. O'Hanlon TP, Lawless OJ, Katzin WE, Feng LJ, **Miller FW**. Restricted and shared patterns of TCR beta-chain gene expression in silicone breast implant capsules and remote sites of tissue inflammation. *J Autoimmun.* 2000;14(4):283-93. doi: 10.1006/jaut.2000.0376. PMID: 10882054.
69. Rider LG*, Artlett CM*, Foster CB, Ahmed A, Neeman T, Chanock SJ, Jimenez SA, **Miller FW**. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. *Clin Exp Immunol.* 2000;121(1):47-52. doi: 10.1046/j.1365-2249.2000.01266.x. PMID: 10886238; PMCID: PMC1905682. *These authors contributed equally.
70. Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, **Miller FW**, Rider LG. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. *Arthritis Rheum.* 2000;43(8):1866-73. doi: 10.1002/1529-0131(200008)43:8<1866::AID-ANR24>3.0.CO;2-6. PMID: 10943878.
71. D'Cruz D, Keser G, Khamashta MA, Direskeneli H, Targoff IN, **Miller F**, Hughes GR. Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. *J Rheumatol.* 2000;27(1):161-4. doi. PMID: 10648033.
72. **Miller FW**, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Jr., Love LA. Approaches for identifying and defining environmentally associated rheumatic disorders. *Arthritis Rheum.* 2000;43(2):243-9. doi: 10.1002/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K. PMID: 10693862.
73. Artlett CM, Ramos R, Jimenez SA, Patterson K, **Miller FW**, Rider LG. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. *Lancet.* 2000;356(9248):2155-6. doi: 10.1016/s0140-6736(00)03499-1.

PMID: 11191545.

74. Shamim EA, **Miller FW**. Familial autoimmunity and the idiopathic inflammatory myopathies. *Curr Rheumatol Rep*. 2000;2(3):201-11. doi: 10.1007/s11926-000-0080-0. PMID: 11123060.
75. Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, Wallace CA, Lindsley CB, Passo MH, Ballinger SH, Bowyer SL, Reed AM, White PH, Katona IM, **Miller FW**, Rider LG*, Feldman BM*, Juvenile Dermatomyositis Disease Activity Collaborative Study G. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *J Rheumatol*. 2001;28(5):1106-11. doi. PMID: 11361197. *These authors contributed equally.
76. Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, **Miller F**, Day R, Lipani J, Brooks P. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. *J Rheumatol*. 2001;28(5):1163-9. doi. PMID: 11361207.
77. **Miller FW***, Rider LG*, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA, International Myositis Outcome Assessment Collaborative Study G. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology (Oxford)*. 2001;40(11):1262-73. doi: 10.1093/rheumatology/40.11.1262. PMID: 11709610. *These authors contributed equally.
78. Artlett CM, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. *Rheumatology (Oxford)*. 2001;40(11):1279-84. doi: 10.1093/rheumatology/40.11.1279. PMID: 11709612.
79. O'Hanlon TP, **Miller FW**. Genomic organization, transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). *Biochem Biophys Res Commun*. 2002;294(3):609-14. doi: 10.1016/S0006-291X(02)00525-9. PMID: 12056811.
80. Shamim EA, Rider LG, Pandey JP, O'Hanlon TP, Jara LJ, Samayoa EA, Burgos-Vargas R, Vazquez-Mellado J, Alcocer-Varela J, Salazar-Paramo

- M, Kutzbach AG, Malley JD, Targoff IN, Garcia-De la Torre I, **Miller FW**. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis Rheum.* 2002;46(7):1885-93. doi: 10.1002/art.10358. PMID: 12124873.
81. Rider LG*, Schiftenbauer AS*, Zito M, Lim KL, Ahmed A, Zemel LS, Rennebohm RM, Passo MH, Summers RM, Hicks JE, Lachenbruch PA, Heyes MP, **Miller FW**, Juvenile Dermatomyositis Disease Activity Collaboration Study G. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. *Clin chem.* 2002;48(10):1681-8. doi. PMID: 12324484. *These authors contributed equally.
 82. Okada S, Weatherhead E, Targoff IN, Wesley R, **Miller FW**. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. *Arthritis Rheum.* 2003;48(8):2285-93. doi: 10.1002/art.11090. PMID: 12905483.
 83. Artlett CM, O'Hanlon TP, Lopez AM, Song YW, **Miller FW**, Rider LG. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. *Arthritis Rheum.* 2003;48(9):2567-72. doi: 10.1002/art.11235. PMID: 13130476.
 84. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, **Miller FW**, Lachenbruch PA, Rider LG, Juvenile Dermatomyositis Disease Activity Collaborative Study G. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2004;50(5):1595-603. doi: 10.1002/art.20179. PMID: 15146430.
 85. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, **Miller F**, International M, Clinical Studies G. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology (Oxford).* 2004;43(1):49-54. Epub 20030716. doi: 10.1093/rheumatology/keg427. PMID: 12867580.
 86. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Bowyer SL, Feldman BM, Hicks J, Katona IM, Lindsley CB, **Miller FW**, Passo MH, Perez MD,

- Reed AM, Wallace CA, White PH, Zemel LS, Lachenbruch PA, Hayes JR, Rider LG, Juvenile Dermatomyositis Disease Activity Collaborative Study G. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. *Arthritis Rheum.* 2004;51(3):365-70. doi: 10.1002/art.20397. PMID: 15188320.
87. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, **Miller FW**, International Myositis A, Clinical Studies G. International consensus on preliminary definitions of improvement in adult and juvenile myositis. *Arthritis Rheum.* 2004;50(7):2281-90. doi: 10.1002/art.20349. PMID: 15248228.
88. O'Hanlon T, Koneru B, Bayat E, Love L, Targoff I, Malley J, Malley K, **Miller F**, Environmental Myositis Study G. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. *Arthritis Rheum.* 2004;50(11):3646-50. doi: 10.1002/art.20587. PMID: 15529361.
89. O'Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Dreyfuss J, Shamim EA, Rider LG, Chanock SJ, Foster CB, Bunch T, Plotz PH, Love LA, **Miller FW**. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. *Medicine.* 2005;84(6):338-49. doi: 10.1097/01.md.0000189818.63141.8c. PMID: 16267409.
90. Chung YL, Rider LG, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, **Miller FW**, Scott DL, Juvenile Dermatomyositis Disease Activity Collaborative Study G. Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005;53(4):565-70. doi: 10.1002/art.21331. PMID: 16082628.
91. Sarkar K, Weinberg CR, Oddis CV, Medsger TA, Jr., Plotz PH, Reveille JD, Arnett FC, Targoff IN, Genth E, Love LA, **Miller FW**. Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. *Arthritis Rheum.* 2005;52(8):2433-8. doi: 10.1002/art.21198. PMID: 16052581.
92. Oddis CV*, Rider LG*, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, **Miller FW**, International Myositis A, Clinical Studies G. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005;52(9):2607-15. doi: 10.1002/art.21291. PMID: 16142757. *These authors contributed

equally.

93. Romisch K, **Miller FW**, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. *Arthritis Res Ther.* 2006;8(2):R39. Epub 20060126. doi: 10.1186/ar1895. PMID: 16469117; PMCID: PMC1526608.
94. Nagaraju K, Rider LG, Fan C, Chen YW, Mitsak M, Rawat R, Patterson K, Grundtman C, **Miller FW**, Plotz PH, Hoffman E, Lundberg IE. Endothelial cell activation and neovascularization are prominent in dermatomyositis. *J Autoimmune Dis.* 2006;3:2. Epub 20060220. doi: 10.1186/1740-2557-3-2. PMID: 16504012; PMCID: PMC1397829.
95. O'Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Rider LG, Chanock SJ, Foster CB, Bunch T, Blackshear PJ, Plotz PH, Love LA, **Miller FW**. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. *Medicine.* 2006;85(2):111-27. doi: 10.1097/01.md.0000217525.82287.eb. PMID: 16609350.
96. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, **Miller FW***, Rider LG*, Childhood Myositis Heterogeneity Study G, International Myositis Collaborative Study G. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. *Arthritis Rheum.* 2006;54(11):3682-9. doi: 10.1002/art.22164. PMID: 17075819. *These authors contributed equally.
97. O'Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, **Miller FW**. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. *Arthritis Rheum.* 2006;54(11):3670-81. doi: 10.1002/art.22205. PMID: 17075818.
98. Mamyrova G, O'Hanlon TP, Monroe JB, Carrick DM, Malley JD, Adams S, Reed AM, Shamim EA, James-Newton L, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. *Arthritis Rheum.* 2006;54(12):3979-87. doi: 10.1002/art.22216. PMID: 17133612; PMCID: PMC2063456.
99. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner

- ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, **Miller FW**, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB, Response Criteria Working G. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. *Biol Blood Marrow Transplant*. 2006;12(3):252-66. doi: 10.1016/j.bbmt.2006.01.008. PMID: 16503494.
100. Vegosen LJ, Weinberg CR, O'Hanlon TP, Targoff IN, **Miller FW**, Rider LG. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. *Arthritis Rheum*. 2007;56(8):2719-28. doi: 10.1002/art.22751. PMID: 17665425; PMCID: PMC2151046.
101. Mamyrova G, Kleiner DE, James-Newton L, Shaham B, **Miller FW**, Rider LG. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. *Arthritis Rheum*. 2007;57(5):881-4. doi: 10.1002/art.22782. PMID: 17530691; PMCID: PMC2099313.
102. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, **Miller FW**, Rider LG, Juvenile Dermatomyositis Disease Activity Collaborative Study G. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. *Rheumatology (Oxford)*. 2007;46(10):1606-11. doi: 10.1093/rheumatology/kem179. PMID: 17890275; PMCID: PMC2598780.
103. Lachenbruch PA, **Miller FW**, Rider LG. Developing international consensus on measures of improvement for patients with myositis. *Stat Methods Med Res*. 2007;16(1):51-64. doi: 10.1177/0962280206070652. PMID: 17338294.
104. Csako G, Costello R, Shamim EA, O'Hanlon TP, Tran A, Clauw DJ, Williams HJ, **Miller FW**. Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study. *Arthritis Res Ther*. 2007;9(5):R95. doi: 10.1186/ar2295. PMID: 17875216; PMCID: PMC2212583.
105. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, **Miller FW**, Rider LG, Juvenile Dermatomyositis

- Disease Activity Collaborative Study G. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. *Arthritis Rheum.* 2008;59(2):214-21. doi: 10.1002/art.23340. PMID: 18240194.
106. Huber AM, Lachenbruch PA, Dugan EM, **Miller FW**, Rider LG, Juvenile Dermatomyositis Disease Activity Collaborative Study G. Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. *Arthritis Rheum.* 2008;59(3):352-6. doi: 10.1002/art.23313. PMID: 18311761; PMCID: PMC2598766.
 107. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Study G. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine.* 2008;87(2):70-86. doi: 10.1097/MD.0b013e31816bc604. PMID: 18344805; PMCID: PMC2674585.
 108. O'Hanlon TP, Rider LG, Schiffenbauer A, Targoff IN, Malley K, Pandey JP, **Miller FW**. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. *Arthritis Rheum.* 2008;58(10):3239-46. doi: 10.1002/art.23899. PMID: 18821675; PMCID: PMC2682358.
 109. Mamyrova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. *Arthritis Rheum.* 2008;58(12):3941-50. doi: 10.1002/art.24039. PMID: 19035492; PMCID: PMC2674642.
 110. Burd CJ, Kinyamu HK, **Miller FW**, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. *J Biol Chem.* 2008;283(50):34976-82. Epub 20081015. doi: 10.1074/jbc.M805383200. PMID: 18922793; PMCID: PMC2596409.
 111. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini B, Cabalar I, Lovell DJ, Wesley R, Plotz PH, **Miller FW**, Hicks JE, Rider LG. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. *Rheumatology (Oxford).* 2009;48(2):134-9. Epub 20081211. doi: 10.1093/rheumatology/ken441. PMID: 19074186; PMCID: PMC2634286.

112. Ball R, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A, Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, **Miller FW**, Braun MM. HLA type and immune response to *Borrelia burgdorferi* outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. *Arthritis Rheum.* 2009;60(4):1179-86. doi: 10.1002/art.24418. PMID: 19333928; PMCID: PMC2750908.
113. Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger Jr. TA, Reveille JD, Arnett FC, Targoff IN, **Miller FW**. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. *Arthritis Rheum.* 2009;60(8):2499-504. doi: <https://doi.org/10.1002/art.24702>. PMID: 19644877; PMCID: PMC2855681.
114. Lachenbruch PA, **Miller FW**, Rider LG. On Determining the Effects of Therapy on Disease Damage in Non-randomized Studies with Multiple Treatments: A study of Juvenile Myositis. *Commun Stat Theory Methods.* 2009;38(18):3268-81. doi: 10.1080/03610920802468681. PMID: 20209035; PMCID: PMC2832328.
115. Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, **Miller FW**, Group I. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. *Arthritis Rheum.* 2009;60(11):3425-35. doi: 10.1002/art.24904. PMID: 19877055; PMCID: PMC2793533.
116. Coyle K, Rother KI, Weise M, Ahmed A, **Miller FW**, Rider LG. Metabolic abnormalities and cardiovascular risk factors in children with myositis. *J Pediatr.* 2009;155(6):882-7. Epub 20090729. doi: 10.1016/j.jpeds.2009.06.009. PMID: 19643439; PMCID: PMC2809424.
117. Okada S, Kamb ML, Pandey JP, Philen RM, Love LA, **Miller FW**. Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. *Arthritis Rheum.* 2009;61(10):1305-11. doi: 10.1002/art.24460. PMID: 19790128; PMCID: PMC2761987.
118. Eidelman N, Boyde A, Bushby AJ, Howell PG, Sun J, Newbury DE, **Miller FW**, Robey PG, Rider LG. Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. *Arthritis Res Ther.* 2009;11(5):R159. Epub 20091026. doi: 10.1186/ar2841. PMID: 19857267; PMCID: PMC2787294.
119. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI,

- Rodriguez-Ubrevia J, Berdasco M, Fraga MF, O'Hanlon TP, Rider LG, Jacinto FV, Lopez-Longo FJ, Dopazo J, Forn M, Peinado MA, Carreno L, Sawalha AH, Harley JB, Siebert R, Esteller M, **Miller FW**, Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. *Genome Res.* 2010;20(2):170-9. Epub 20091222. doi: 10.1101/gr.100289.109. PMID: 20028698; PMCID: PMC2813473.
120. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, **Miller FW**, Hicks JE. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. *Arthritis Care Res (Hoboken).* 2010;62(4):465-72. doi: 10.1002/acr.20035. PMID: 20391500; PMCID: PMC2924143.
121. Rider LG, Wu L, Mamyrova G, Targoff IN, **Miller FW**, Childhood Myositis Heterogeneity Collaborative Study G. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. *Rheumatology (Oxford).* 2010;49(12):2381-90. Epub 20100827. doi: 10.1093/rheumatology/keq277. PMID: 20802007; PMCID: PMC2981509.
122. O'Hanlon TP, Rider LG, Gan L, Fannin R, Paules RS, Umbach DM, Weinberg CR, Shah RR, Mav D, Gourley MF, **Miller FW**. Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. *Arthritis Res Ther.* 2011;13(2):R69. Epub 20110426. doi: 10.1186/ar3330. PMID: 21521520; PMCID: PMC3132064.
123. Perdivara I, Peddada SD, **Miller FW**, Tomer KB, Deterding LJ. Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes. *J Proteome Res.* 2011;10(7):2969-78. Epub 20110608. doi: 10.1021/pr200397h. PMID: 21609021; PMCID: PMC3137520.
124. Ali MA, Dale JK, Kozak CA, Goldbach-Mansky R, **Miller FW**, Straus SE, Cohen JI. Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. *Virology.* 2011;8:450. Epub 20110924. doi: 10.1186/1743-422x-8-450. PMID: 21943244; PMCID: PMC3210120.
125. Rider LG, **Miller FW**. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. *JAMA.* 2011;305(2):183-90. doi: 10.1001/jama.2010.1977. PMID: 21224460; PMCID: PMC4047218.

126. Allen JA, Peterson A, Sufit R, Hinchcliff ME, Mahoney JM, Wood TA, **Miller FW**, Whitfield ML, Varga J. Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. *Arthritis Rheum.* 2011;63(11):3633-9. doi: 10.1002/art.30514. PMID: 21702023; PMCID: PMC3848710.
127. O'Hanlon TP, Li Z, Gan L, Gourley MF, Rider LG, **Miller FW**. Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases. *Arthritis Res Ther.* 2011;13(6):R181. Epub 20111101. doi: 10.1186/ar3506. PMID: 22044644; PMCID: PMC3315681.
128. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, Jusko TA, Walker NJ, Germolec DR, Whitt IZ, Crockett PW, Pauley BA, Chan JY, Ross SJ, Birnbaum LS, Zeldin DC, **Miller FW**. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. *Arthritis Rheum.* 2012;64(7):2319-27. doi: 10.1002/art.34380. PMID: 22237992; PMCID: PMC3330150.
129. Forsberg LA, Rasi C, Razzaghian HR, Pakalapati G, Waite L, Thilbeault KS, Ronowicz A, Wineinger NE, Tiwari HK, Boomsma D, Westerman MP, Harris JR, Lyle R, Essand M, Eriksson F, Assimes TL, Iribarren C, Strachan E, O'Hanlon TP, Rider LG, **Miller FW**, Giedraitis V, Lannfelt L, Ingelsson M, Piotrowski A, Pedersen NL, Absher D, Dumanski JP. Age-related somatic structural changes in the nuclear genome of human blood cells. *Am J Hum Genet.* 2012;90(2):217-28. Epub 20120202. doi: 10.1016/j.ajhg.2011.12.009. PMID: 22305530; PMCID: PMC3276669.
130. Volochayev R, Csako G, Wesley R, Rider LG, **Miller FW**. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. *Open Rheumatol J.* 2012;6:54-63. Epub 20120601. doi: 10.2174/1874312901206010054. PMID: 22723809; PMCID: PMC3377888.
131. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, **Miller FW**, Rider LG, with the Childhood Myositis Heterogeneity Collaborative Study G. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine.* 2013;92(1):25-41. Epub 2012/12/25. doi: 10.1097/MD.0b013e31827f264d. PMID: 23263716; PMCID: PMC4580479.
132. Parks CG, D'Aloisio AA, DeRoo LA, Huiber K, Rider LG, **Miller FW**, Sandler DP. Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. *Ann Rheum Dis.* 2013;72(3):350-6. Epub 20120514. doi: 10.1136/annrheumdis-2011-201083. PMID: 22586176; PMCID: PMC5029277.

133. Rider LG, Shah M*, Mamyrova G*, Huber AM, Rice MM, Targoff IN, **Miller FW**, Childhood Myositis Heterogeneity Collaborative Study G. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine*. 2013;92(4):223-43. doi: 10.1097/MD.0b013e31829d08f9. PMID: 23877355; PMCID: PMC3721421. *These authors contributed equally.
134. Shah M, Targoff IN, Rice MM, **Miller FW**, Rider LG, Group wtCMHCS. Brief Report: Ultraviolet Radiation Exposure Is Associated With Clinical and Autoantibody Phenotypes in Juvenile Myositis. *Arthritis Rheum*. 2013;65(7):1934-41. doi: <https://doi.org/10.1002/art.37985>. PMID: 23658122; PMCID: PMC3727975.
135. Razzaghatian HR, Forsberg LA, Prakash KR, Przerada S, Paprocka H, Zywicka A, Westerman MP, Pedersen NL, O'Hanlon TP, Rider LG, **Miller FW**, Srutek E, Jankowski M, Zegarski W, Piotrowski A, Absher D, Dumanski JP. Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the IL10R β and IFNAR1 genes. *PLoS One*. 2013;8(9):e67752. Epub 20130904. doi: 10.1371/journal.pone.0067752. PMID: 24023707; PMCID: PMC3762855.
136. **Miller FW***, Cooper RG*, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, O'Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI**, Gregersen PK**, Myositis Genetics C. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. *Arthritis Rheum*. 2013;65(12):3239-47. doi: 10.1002/art.38137. PMID: 23983088; PMCID: PMC3934004. *,**These authors contributed equally to this work. (*NIEHS Environmental Factor November 2013 Intramural Paper of the Month*)
137. Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G. Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. *Arthritis Care Res (Hoboken)*. 2013;65(12):1969-75. doi: 10.1002/acr.22088. PMID: 23925923; PMCID: PMC5083635.
138. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, **Miller FW**, Rockette HE, Group RIMS. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis Rheum*. 2013;65(2):314-24. doi: 10.1002/art.37754. PMID: 23124935; PMCID:

PMC3558563.

139. Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. *Arthritis Care Res (Hoboken)*. 2014;66(5):732-40. doi: 10.1002/acr.22212. PMID: 24151254; PMCID: PMC4646219.
140. Gan L, O'Hanlon TP, Gordon AS, Rider LG, **Miller FW**, Burbelo PD. Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis. *BMC Musculoskelet Disord*. 2014;15:67. Epub 20140306. doi: 10.1186/1471-2474-15-67. PMID: 24602337; PMCID: PMC3973849.
141. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, **Miller FW**, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR, Group C-ISI. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax*. 2014;69(5):428-36. Epub 20131224. doi: 10.1136/thoraxjnl-2013-204202. PMID: 24368713; PMCID: PMC3995282.
142. Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, **Miller FW**. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. *Clin Exp Rheumatol*. 2014;32(5):689-96. Epub 20140728. doi. PMID: 25068290; PMCID: PMC4644185.
143. Parks CG, **Miller FW**, Satoh M, Chan EK, Andrushchenko Z, Birnbaum LS, Jusko TA, Kissling GE, Patel MD, Rose KM, Weinberg C, Zeldin DC, Sandler DP. Reproductive and hormonal risk factors for antinuclear antibodies (ANA) in a representative sample of U.S. women. *Cancer Epidemiol Biomarkers Prev*. 2014;23(11):2492-502. Epub 20140801. doi: 10.1158/1055-9965.Epi-14-0429. PMID: 25086100; PMCID: PMC4361940.
144. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, **Miller FW**, Rider LG, Harris-Love MO, Levesque MC, Group RIMS,

- Oddis CV. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. *Arthritis Rheumatol.* 2014;66(3):740-9. doi: 10.1002/art.38270. PMID: 24574235; PMCID: PMC3987896.
145. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; **OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group**; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. *J Rheumatol.* 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. Epub 2014 Feb 1. PMID: 24488412; PMCID: PMC4369780.
146. Dinse GE, Jusko TA, Ho LA, Annam K, Graubard BI, Hertz-Picciotto I, **Miller FW**, Gillespie BW, Weinberg CR. Accommodating measurements below a limit of detection: a novel application of Cox regression. *Am J Epidemiol.* 2014;179(8):1018-24. Epub 20140304. doi: 10.1093/aje/kwu017. PMID: 24671072; PMCID: PMC3966718.
147. Jani M, Massey J, Wedderburn LR, Vencovsky J, Danko K, Lundberg IE, Padyukov L, Selva-O'Callaghan A, Radstake T, Platt H, Warren RB, Griffiths CE, Lee A, Gregersen PK, **Miller FW**, Ollier WE, Cooper RG, Chinoy H, Lamb JA, Eumyonet. Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. *Ann Rheum Dis.* 2014;73(9):1750-2. Epub 20140507. doi: 10.1136/annrheumdis-2014-205440. PMID: 24812289; PMCID: PMC4471138.
148. Parks CG, **Miller FW**, Pollard KM, Selmi C, Germolec D, Joyce K, Rose NR, Humble MC. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. *Int J Mol Sci.* 2014;15(8):14269-97. Epub 20140815. doi: 10.3390/ijms150814269. PMID: 25196523; PMCID: PMC4159850.
149. **Miller FW**, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake TR, Isenberg DA, Chinoy H, Ollier WE, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI, Myositis Genetics C. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. *Genes Immun.* 2015;16(7):470-80. Epub 20150820. doi: 10.1038/gene.2015.28. PMID: 26291516; PMCID: PMC4840953.

150. Wing S, Rider LG, Johnson JR, **Miller FW**, Matteson EL, Crowson CS, Gabriel SE. Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence? *BMJ Open*. 2015;5(5):e006636. Epub 20150515. doi: 10.1136/bmjopen-2014-006636. PMID: 25979866; PMCID: PMC4442155.
151. Artlett CM, Sassi-Gaha S, Ramos RC, **Miller FW**, Rider LG. Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies or muscular dystrophy. *Arthritis Res Ther*. 2015;17(1):238. Epub 20150904. doi: 10.1186/s13075-015-0732-0. PMID: 26338728; PMCID: PMC4558637.
152. Gan L, O'Hanlon TP, Lai Z, Fannin R, Weller ML, Rider LG, Chiorini JA, **Miller FW**. Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. *PLoS One*. 2015;10(11):e0142486. Epub 20151110. doi: 10.1371/journal.pone.0142486. PMID: 26556803; PMCID: PMC4640563.
153. Dinse GE, Jusko TA, Whitt IZ, Co CA, Parks CG, Satoh M, Chan EK, Rose KM, Walker NJ, Birnbaum LS, Zeldin DC, Weinberg CR, **Miller FW**. Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999-2004. *Environ Health Perspect*. 2016;124(4):426-36. Epub 20150807. doi: 10.1289/ehp.1409345. PMID: 26252071; PMCID: PMC4829978.
154. Rothwell S, Cooper RG, Lundberg IE, **Miller FW**, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Rider LG, Cobb J, Platt H, Molberg O, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleeker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA, Myositis Genetics C. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. *Ann Rheum Dis*. 2016;75(8):1558-66. Epub 20150911. doi: 10.1136/annrheumdis-2015-208119. PMID: 26362759; PMCID: PMC5300750.
155. Yao L, Yip AL, Shrader JA, Mesdaghinia S, Volochayev R, Jansen AV, **Miller FW**, Rider LG. Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. *Rheumatology (Oxford)*. 2016;55(3):441-9. Epub 20150927. doi: 10.1093/rheumatology/kev344. PMID: 26412808; PMCID: PMC4757924.

156. Lintner KE, Patwardhan A*, Rider LG*, Abdul-Aziz R, Wu YL, Lundstrom E, Padyukov L, Zhou B, Alhomosh A, Newsom D, White P, Jones KB, O'Hanlon TP, **Miller FW**, Spencer CH, Yu CY. Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis. *Ann Rheum Dis*. 2016;75(9):1599-606. Epub 20151022. doi: 10.1136/annrheumdis-2015-207762. PMID: 26493816; PMCID: PMC5321713. *These authors contributed equally.
157. Nagaraju K, Ghimbovschi S, Rayavarapu S, Phadke A, Rider LG, Hoffman EP, **Miller FW**. Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. *Rheumatology (Oxford)*. 2016;55(9):1673-80. Epub 20160523. doi: 10.1093/rheumatology/kew213. PMID: 27215813; PMCID: PMC5854096.
158. Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, **Miller FW**, van Royen-Kerkhof A, Rider LG, Childhood Myositis Heterogeneity Study G. Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. *Arthritis Rheumatol*. 2016;68(3):761-8. Epub 2015/10/17. doi: 10.1002/art.39466. PMID: 26474155; PMCID: PMC4767657.
159. Grau-Pérez M, Kuo CC, Spratlen M, Thayer KA, Mendez MA, Hamman RF, Dabelea D, Adgate JL, Knowler WC, Bell RA, **Miller FW**, Liese AD, Zhang C, Douillet C, Drobná Z, Mayer-Davis EJ, Styblo M, Navas-Acien A. The Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth: The SEARCH Case-Control Study. *Diabetes Care*. 2017;40(1):46-53. Epub 20161103. doi: 10.2337/dc16-0810. PMID: 27810988; PMCID: PMC5180459.
160. Hong KM, Kim HK, Park SY, Poojan S, Kim MK, Sung J, Tsao BP, Grossman JM, Rullo OJ, Woo JM, McCurdy DK, Rider LG, **Miller FW**, Song YW. CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3zeta-chain expression in T cells. *Rheumatology (Oxford)*. 2017;56(3):467-76. Epub 2016/12/13. doi: 10.1093/rheumatology/kew405. PMID: 27940592; PMCID: PMC5850282.
161. Rider LG*, Aggarwal R**, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Magalhaes CS, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, **Miller FW**, Vencovsky J**, Ruperto N**, International Myositis A, Clinical

- Studies G, the Paediatric Rheumatology International Trials O. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis Rheumatol.* 2017;69(5):911-23. Epub 20170406. doi: 10.1002/art.40060. PMID: 28382778; PMCID: PMC5577002. *,**These authors contributed equally to this work.
162. Aggarwal R*, Rider LG*, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, García-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, **Miller FW****, Vencovsky J**. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis Rheumatol.* 2017;69(5):898-910. Epub 2017/04/07. doi: 10.1002/art.40064. PMID: 28382787; PMCID: PMC5407906. *,**These authors contributed equally to this work.
163. Rider LG*, Aggarwal R*, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, **Miller FW**, Vencovsky J**, Ruperto N**, International Myositis A, Clinical Studies G, the Paediatric Rheumatology International Trials O. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Ann Rheum Dis.* 2017;76(5):782-91. Epub 2017/04/08. doi: 10.1136/annrhumdis-2017-211401. PMID: 28385804; PMCID: PMC5517365. *,**These authors contributed equally to this work.
164. Aggarwal R*, Rider LG*, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, Garcia-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, **Miller FW****, Vencovsky J**, International Myositis A, Clinical Studies G, the Paediatric Rheumatology International Trials O. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical

response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Ann Rheum Dis*. 2017;76(5):792-801. Epub 2017/04/07. doi: 10.1136/annrheumdis-2017-211400. PMID: 28385805; PMCID: PMC5496443. *,**These authors contributed equally to this work.

165. Kishi T*, Rider LG*, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, **Miller FW**, Mammen AL, Childhood Myositis Heterogeneity Study G. Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. *Arthritis Care Res (Hoboken)*. 2017;69(7):1088-94. Epub 2017/01/28. doi: 10.1002/acr.23113. PMID: 28129483; PMCID: PMC5487292. *These authors contributed equally.
166. Rider LG*, Ruperto N*, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, Garcia-De la Torre I, Reed AM, Wook Song Y, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, **Miller FW**, Vencovsky J**, Aggarwal R**, International Myositis A, Clinical Studies G, the Paediatric Rheumatology International Trials O. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. *Rheumatology (Oxford)*. 2017;56(11):1884-93. doi: 10.1093/rheumatology/kex226. PMID: 28977549; PMCID: PMC5850656. *,**These authors contributed equally to this work.
167. Feldon M, Farhadi PN, Brunner HI, Itert L, Goldberg B, Faiq A, Wilkerson J, Rose KM, Rider LG, **Miller FW***, Giannini EH*. Predictors of Reduced Health-Related Quality of Life in Adult Patients With Idiopathic Inflammatory Myopathies. *Arthritis Care Res (Hoboken)*. 2017;69(11):1743-50. Epub 20170921. doi: 10.1002/acr.23198. PMID: 28118525; PMCID: PMC5524619. *These authors contributed equally.
168. Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscone-Schreiber LG, Jung LK, **Miller FW**, Katz JD. Environmental factors associated with disease flare in juvenile and adult dermatomyositis. *Rheumatology (Oxford)*. 2017;56(8):1342-7. Epub 2017/04/27. doi: 10.1093/rheumatology/kex162. PMID: 28444299; PMCID: PMC5850835.
169. Bottai M, Tjarnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman

- BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, **Miller FW**, Rider LG, Lundberg IE, International Myositis Classification Criteria Project consortium tEr, the Juvenile Dermatomyositis Cohort Biomarker S, Repository. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. *RMD open*. 2017;3(2):e000507. Epub 20171114. doi: 10.1136/rmdopen-2017-000507. PMID: 29177080; PMCID: PMC5687535.
170. Lundberg IE, Tjarnlund A*, Bottai M*, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, **Miller FW**§, Rider LG§, International Myositis Classification Criteria Project consortium tEr, The Juvenile Dermatomyositis Cohort Biomarker S, Repository. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. *Ann Rheum Dis*. 2017;76(12):1955-64. Epub 20171027. doi: 10.1136/annrheumdis-2017-211468. PMID: 29079590; PMCID: PMC5736307. *,§These authors contributed equally to this work.
171. Lundberg IE, Tjarnlund A*, Bottai M*, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, **Miller FW**, Rider LG§, International Myositis Classification Criteria Project Consortium tER, the Juvenile Dermatomyositis Cohort Biomarker S, Repository. 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. *Arthritis Rheumatol*. 2017;69(12):2271-82. Epub 20171027. doi: 10.1002/art.40320. PMID: 29106061; PMCID: PMC5846474. *,§These authors contributed equally to this work.
172. Dinse GE, Parks CG, Weinberg CR, Meier HCS, Co CA, Chan EKL, **Miller FW**. Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004). *PLoS One*. 2017;12(10):e0185977. Epub 20171009. doi:

- 10.1371/journal.pone.0185977. PMID: 29016697; PMCID: PMC5633179.
173. Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, Shrader J, Cabalar IV, Faghihi-Kashani S, Harris-Love MO, Plotz PH, **Miller FW**, Gourley M. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. *Semin Arthritis Rheum.* 2018;47(6):858-64. Epub 20171016. doi: 10.1016/j.semarthrit.2017.10.010. PMID: 29174792; PMCID: PMC6208161.
 174. Yeker RM*, Pinal-Fernandez I*, Kishi T, Pak K, Targoff IN, **Miller FW**, Rider LG§, Mammen AL§, Childhood Myositis Heterogeneity Collaborative Study G. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis. *Ann Rheum Dis.* 2018;77(5):714-9. Epub 20180123. doi: 10.1136/annrheumdis-2017-212436. PMID: 29363513; PMCID: PMC5898976. *,§These authors contributed equally to this work.
 175. Schiffenbauer A, Faghihi-Kashani S, O'Hanlon TP, Flegel WA, Adams SD, Targoff IN, Oddis CV, Ytterberg SR, Aggarwal R, Christopher-Stine L, Shamim EA, Dellaripa PF, Danoff SK, Mammen AL, **Miller FW**. The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. *Semin Arthritis Rheum.* 2018;48(3):504-12. Epub 20180214. doi: 10.1016/j.semarthrit.2018.02.003. PMID: 29703532; PMCID: PMC6133760.
 176. Kishi T, Bayat N, Ward MM, Huber AM, Wu L, Mamyrova G, Targoff IN, Warren-Hicks WJ, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Study G. Medications received by patients with juvenile dermatomyositis. *Semin Arthritis Rheum.* 2018;48(3):513-22. Epub 20180328. doi: 10.1016/j.semarthrit.2018.03.016. PMID: 29773230; PMCID: PMC6162169.
 177. Dinse GE, Parks CG, Meier HCS, Co CA, Chan EKL, Jusko TA, Yeh J, **Miller FW**. Prescription medication use and antinuclear antibodies in the United States, 1999-2004. *J Autoimmun.* 2018;92:93-103. Epub 20180518. doi: 10.1016/j.jaut.2018.05.006. PMID: 29779929; PMCID: PMC6054905.
 178. Parkes JE, Rothwell S, Oldroyd A, Chinoy H, Lamb JA; **Myositis Genetics Consortium (MYOGEN)**. Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1- γ autoantibodies in adult patients with myositis. *Arthritis Res Ther.* 2018 Jun 8;20(1):117. doi: 10.1186/s13075-018-1617-9. PMID: 29884237; PMCID: PMC5994128.

179. Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; **Childhood Myositis Heterogeneity Collaborative Study Group**. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. *Rheumatology (Oxford)*. 2018 Nov 1;57(11):1956-1963. doi: 10.1093/rheumatology/key190. PMID: 30016492; PMCID: PMC6199536.
180. Acosta-Herrera M, Kerick M, González-Serna D; **Myositis Genetics Consortium**; Scleroderma Genetics Consortium; Wijmenga C, Franke A, Gregersen PK, Padyukov L, Worthington J, Vyse TJ, Alarcón-Riquelme ME, Mayes MD, Martin J. Genome-wide meta-analysis reveals shared new loci in systemic seropositive rheumatic diseases. *Ann Rheum Dis*. 2019 Mar;78(3):311-319. doi: 10.1136/annrheumdis-2018-214127. Epub 2018 Dec 20. PMID: 30573655; PMCID: PMC6800208.
181. Sabbagh S*, Pinal-Fernandez I*, Kishi T, Targoff IN, **Miller FW**, Rider LG**, Mammen AL**, Childhood Myositis Heterogeneity Collaborative Study G. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. *Ann Rheum Dis*. 2019;78(7):988-95. Epub 20190424. doi: 10.1136/annrheumdis-2018-215004. PMID: 31018961; PMCID: PMC7570952. *,**These authors contributed equally to this work.
182. Rothwell S, Chinoy H, Lamb JA, **Miller FW**, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovsky J, Deakin CT, Danko K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg O, Benveniste O, Mathiesen PR, Radstake T, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE, Myositis Genetics C. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. *Ann Rheum Dis*. 2019;78(7):996-1002. Epub 20190528. doi: 10.1136/annrheumdis-2019-215046. PMID: 31138531; PMCID: PMC6585280.
183. Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, **Miller FW**, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Paik J, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL. Identification of distinctive interferon gene signatures in different types of myositis. *Neurology*. 2019;93(12):e1193-e204. Epub 20190821. doi: 10.1212/wnl.00000000000008128. PMID: 31434690; PMCID: PMC6808530.
184. Sabbagh S, Pinal Fernandez I, **Miller FW**, Rider LG, Mammen AL. Response to: 'Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile

- myositis' by Sabbagh S et al' by Yang et al. *Ann Rheum Dis.* 2020;79(8):e97. Epub 20190617. doi: 10.1136/annrheumdis-2019-215693. PMID: 31208959; PMCID: PMC8466717.
185. Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, Targoff IN, Schiffenbauer A, **Miller FW**, Simmens SJ, Curiel R, Jones OY, Rider LG. Long-term outcomes in Juvenile Myositis patients. *Semin Arthritis Rheum.* 2020;50(1):149-55. Epub 20190628. doi: 10.1016/j.semarthrit.2019.06.014. PMID: 31303436; PMCID: PMC6934928.
 186. Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, Centola M, **Miller FW**, Rider LG. Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. *J Rheumatol.* 2020;47(7):1011-8. Epub 20190801. doi: 10.3899/jrheum.181275. PMID: 31371656; PMCID: PMC6994352.
 187. Parks CG, Wilkerson J, Rose KM, Faiq A, Noroozi Farhadi P, Long CS, Bayat N, Brunner HI, Goldberg B, McGrath JA, **Miller FW**, Rider LG. Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. *Arthritis Care Res (Hoboken).* 2020;72(11):1636-44. Epub 2019/09/04. doi: 10.1002/acr.24059. PMID: 31478597; PMCID: PMC7051886.
 188. Schurman SH, O'Hanlon TP, McGrath JA, Gruzdev A, Bektas A, Xu H, Garantziotis S, Zeldin DC, **Miller FW**. Transethnic associations among immune-mediated diseases and single-nucleotide polymorphisms of the aryl hydrocarbon response gene ARNT and the PTPN22 immune regulatory gene. *J Autoimmun.* 2020;107:102363. Epub 20191121. doi: 10.1016/j.jaut.2019.102363. PMID: 31759816; PMCID: PMC7237321.
 189. Dillon CF, Weisman MH, **Miller FW**. Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014. *PLoS One.* 2020;15(1):e0226516. Epub 20200113. doi: 10.1371/journal.pone.0226516. PMID: 31929535; PMCID: PMC6957172.
 190. Seto N, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, Pak K, Purmalek MM, Hosono Y, Fernandes-Cerqueira C, Gowda P, Arnett N, Gorbach A, Benveniste O, Gomez-Martin D, Selva-O'Callaghan A, Milisenda JC, Grau-Junyent JM, Christopher-Stine L, **Miller FW**, Lundberg IE, Kahlenberg JM, Schiffenbauer AI, Mammen A, Rider LG, Kaplan MJ. Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. *JCI Insight.* 2020;5(3). Epub 20200213. doi: 10.1172/jci.insight.134189. PMID: 31945019; PMCID: PMC7098779.

191. Meier HCS, **Miller FW**, Dinse GE, Weinberg CR, Cho CC, Parks CG. Helicobacter pylori seropositivity is associated with antinuclear antibodies in US adults, NHANES 1999-2000. *Epidemiol Infect.* 2020;148:e20. Epub 20200205. doi: 10.1017/s0950268820000126. PMID: 32019616; PMCID: PMC7019483.
192. Smith MA, Chiang CC, Zerrouki K, Rahman S, White WI, Streicher K, Rees WA, Schiffenbauer A, Rider LG, **Miller FW**, Manna Z, Hasni S, Kaplan MJ, Siegel R, Sinibaldi D, Sanjuan MA, Casey KA. Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. *Sci Rep.* 2020;10(1):4462. Epub 20200310. doi: 10.1038/s41598-020-60563-9. PMID: 32157125; PMCID: PMC7064569.
193. Kim H, Gunter-Rahman F, McGrath JA, Lee E, de Jesus AA, Targoff IN, Huang Y, O'Hanlon TP, Tsai WL, Gadina M, **Miller FW**, Goldbach-Mansky R*, Rider LG*. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. *Arthritis Res Ther.* 2020;22(1):69. Epub 20200406. doi: 10.1186/s13075-020-02160-9. PMID: 32252809; PMCID: PMC7137415. *These authors contributed equally.
194. Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, **Miller FW**, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Carrion-Ribas C, Paik JJ, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL. Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. *Ann Rheum Dis.* 2020;79(9):1234-42. Epub 20200616. doi: 10.1136/annrheumdis-2019-216599. PMID: 32546599; PMCID: PMC Journal – In Process.
195. Milisenda JC, Pinal-Fernandez I, Lloyd TE, Grau JM, **Miller FW**, Selva-O'Callaghan A, Christopher-Stine L, Stenzel W, Mammen AL, Corse AM. Accumulation of autophagosome cargo protein p62 is common in idiopathic inflammatory myopathies. *Clin Exp Rheumatol.* 2021;39(2):351-6. Epub 20200901. doi: 10.55563/clinexprheumatol/6mp37n. PMID: 32896253; PMCID: PMC9062971.
196. Kishi T, Warren-Hicks W, Bayat N, Targoff IN, Huber AM, Ward MM, Rider LG, with the **Childhood Myositis Heterogeneity Study G**. Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. *Rheumatology (Oxford).* 2021;60(5):2134-45. doi: 10.1093/rheumatology/keaa371. PMID: 33067611; PMCID: PMC8121446.
197. Mamyrova G, Kishi T, Shi M, Targoff IN, Huber AM, Curiel RV, **Miller FW**, Rider LG, Childhood Myositis Heterogeneity Collaborative Study G. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute

- a distinct phenotype in North America. *Rheumatology (Oxford)*. 2021;60(4):1839-49. doi: 10.1093/rheumatology/keaa429. PMID: 33140079; PMCID: PMC8023991.
198. Foley JF, Elgart B, Alex Merrick B, Phadke DP, Cook ME, Malphurs JA, Solomon GG, Shah RR, Fessler MB, **Miller FW**, Gerrish KE. Whole genome sequencing of low input circulating cell-free DNA obtained from normal human subjects. *Physiol Rep*. 2021;9(15):e14993. doi: 10.14814/phy2.14993. PMID: 34350716; PMCID: PMC8339531.
 199. Fecho K, Bizon C, **Miller F**, Schurman S, Schmitt C, Xue W, Morton K, Wang P, Tropsha A. A Biomedical Knowledge Graph System to Propose Mechanistic Hypotheses for Real-World Environmental Health Observations: Cohort Study and Informatics Application. *JMIR Med Inform*. 2021;9(7):e26714. Epub 20210720. doi: 10.2196/26714. PMID: 34283031; PMCID: PMC8335603.
 200. van Drongelen V, Scavuzzi BM, Nogueira SV, **Miller FW**, Sawalha AH, Holoshitz J. HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization. *Sci Rep*. 2021;11(1):2599. Epub 20210128. doi: 10.1038/s41598-021-82195-3. PMID: 33510427; PMCID: PMC7844024.
 201. Sabbagh SE, Pinal-Fernandez I, Casal-Dominguez M, Albayda J, Paik JJ, **Miller FW**, Rider LG, Mammen AL, Christopher-Stine L, Johns Hopkins Myositis Center G. Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis. *Clin Rheumatol*. 2021;40(10):4095-100. Epub 20210413. doi: 10.1007/s10067-021-05730-7. PMID: 33851273; PMCID: PMC8463345.
 202. Weisman MH, Stens O, Kim HS, Hou JK, **Miller FW**, Dillon CF. Axial Pain and Arthritis in Diagnosed Inflammatory Bowel Disease: US National Health and Nutrition Examination Survey Data. *Mayo Clin Proc Innov Qual Outcomes*. 2022;6(5):443-9. Epub 20220916. doi: 10.1016/j.mayocpiqo.2022.04.007. PMID: 36147868; PMCID: PMC9485826.
 203. Pinal-Fernandez I, Pak K, Gil-Vila A, Baucells A, Plotz B, Casal-Dominguez M, Derfoul A, Martinez-Carretero MA, Selva-O'Callaghan A, Sabbagh S, Casciola-Rosen L, Albayda J, Paik J, Tiniakou E, Danoff SK, Lloyd TE, **Miller FW**, Rider LG, Christopher-Stine L, Mammen AL, Childhood Myositis Heterogeneity Collaborative Study G. Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. *Arthritis Rheumatol*. 2022;74(2):358-64. Epub

20211226. doi: 10.1002/art.41931. PMID: 34313394; PMCID: PMC8792092.
204. Karasawa R, Yudoh K, Sato T, Tanaka M, Tamaki M, Sabbagh SE, O'Hanlon TP, Noroozi-Farhadi P, Targoff IN, Flegel WA, Mammen AL, **Miller FW**, Hicar MD, Rider LG, Jarvis JN. Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. *Rheumatology (Oxford)*. 2022;61(7):2969-77. doi: 10.1093/rheumatology/keab846. PMID: 34791087; PMCID: PMC9258543.
205. Scalabrini JC, Schiftenbauer AI, Farhadi PN, Volochayev R, Bayat N, Jansen A, Targoff IN, **Miller FW**, Rider LG. Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. *Pediatr Rheumatol Online J*. 2022;20(1):28. Epub 20220412. doi: 10.1186/s12969-022-00684-9. PMID: 35414090; PMCID: PMC9004071.
206. Scofield RH, Lewis VM, Cavitt J, Kurien BT, Assassi S, Martin J, Gorlova O, Gregersen P, Lee A, Rider LG, O'Hanlon T, Rothwell S, Lilleker J, Myositis Genetics Consortium XL, Kochi Y, Terao C, Igoe A, Stevens W, Sahhar J, Roddy J, Rischmueller M, Lester S, Proudman S, Chen S, Brown MA, Mayes MD, Lamb JA, **Miller FW**. 47XXY and 47XXX in Scleroderma and Myositis. *ACR Open Rheumatol*. 2022;4(6):528-33. Epub 20220329. doi: 10.1002/acr2.11413. PMID: 35352506; PMCID: PMC9190224.
207. Mamyrova G, McBride E, Yao L, Shrader JA, Jain M, Yao J, Curiel RV, **Miller FW**, Harris-Love MO, Rider LG. Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM). *Rheumatology (Oxford)*. 2022;61(SI):SI48-SI55. doi: 10.1093/rheumatology/keab833. PMID: 34791066; PMCID: PMC9015026.
208. Deakin CT, Bowes J, Rider LG, **Miller FW**, Pachman LM, Sanner H, Rouster-Stevens K, Mamyrova G, Curiel R, Feldman BM, Huber AM, Reed AM, Schmeling H, Cook CG, Marshall LR, Li Wilkinson MG, Eyre S, Raychaudhuri S*, Wedderburn LR*, Juvenile Dermatomyositis C, Biomarker Study tCMHSG, the Myositis Genetics C. Association with HLA-DRbeta1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. *Hum Mol Genet*. 2022;31(14):2471-81. doi: 10.1093/hmg/ddac019. PMID: 35094092; PMCID: PMC9307311. *These authors contributed equally.
209. Meier HCS, Sandler DP, Wilkerson J, **Miller FW**, Dinse GE, Parks CG. Hygiene Hypothesis Indicators and Prevalence of Antinuclear Antibodies in US Adolescents. *Front Immunol*. 2022;13:789379. Epub 20220128. doi: 10.3389/fimmu.2022.789379. PMID: 35154106; PMCID: PMC8832391.

210. Zanframundo G, Faghihi-Kashani S, Scirè CA, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen A, McHugh N, **Miller FW**, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Selva-O'Callaghan A, Werth VP, Sakellariou G, Aggarwal R, Cavagna L. Defining anti-synthetase syndrome: a systematic literature review. *Clin Exp Rheumatol*. 2022;40(2):309-19. Epub 20220225. doi: 10.55563/clinexprheumatol/8xj0b9. PMID: 35225224; PMCID: PMC Journal – In Process.
211. Hossain MM, Wilkerson J, McGrath JA, Farhadi PN, Brokamp C, Khan MTF, Goldberg B, Brunner HI, Macaluso M, **Miller FW**, Rider LG. The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. *Front Med (Lausanne)*. 2022;9:842586. Epub 20220316. doi: 10.3389/fmed.2022.842586. PMID: 35372396; PMCID: PMC8966380.
212. Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, Nazir S, Ritter R, Sirotych E, Kennedy K, Larche MJ, Levine M, Sattui SE, Liew JW, Harrison CO, Moni TT, Miller AK, Putman M, Hausmann J, Simard JF, Sparks JA, **Miller FW**, Group C-GRAVS. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. *Rheumatology (Oxford)*. 2022;61(S12):SI143-SI150. doi: 10.1093/rheumatology/keac249. PMID: 35460240; PMCID: PMC9248066.
213. Dinse GE, Co CA, Parks CG, Weinberg CR, Xie G, Chan EKL, Birnbaum LS, **Miller FW**. Expanded assessment of xenobiotic associations with antinuclear antibodies in the United States, 1988-2012. *Environ Int*. 2022;166:107376. Epub 20220627. doi: 10.1016/j.envint.2022.107376. PMID: 35785669; PMCID: PMC9792625.
214. Miglioranza Scavuzzi B, van Drongelen V, Kaur B, Fox JC, Liu J, Mesquita-Ferrari RA, Kahlenberg JM, Farkash EA, Benavides F, **Miller FW**, Sawalha AH, Holoshitz J. The lupus susceptibility allele DRB1*03:01 encodes a disease-driving epitope. *Commun Biol*. 2022;5(1):751. Epub 20220728. doi: 10.1038/s42003-022-03717-x. PMID: 35902632; PMCID: PMC9334592.
215. Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, Chan EKL, **Miller FW**. Increasing Prevalence of Antinuclear Antibodies in the United States. *Arthritis Rheumatol*. 2022;74(12):2032-41. Epub 20221019. doi: 10.1002/art.42330. PMID: 36054084; PMCID: PMC Journal – In Process.

216. Parks CG, Meier HCS, Jusko TA, Wilkerson J, **Miller FW**, Sandler DP. Benzophenone-3 and antinuclear antibodies in U.S. adolescents and adults ages 12-39 years. *Front Immunol.* 2022;13:958527. Epub 20220913. doi: 10.3389/fimmu.2022.958527. PMID: 36177040; PMCID: PMC9513228.
217. Parkes JE, Boehler JF, Li N, Kendra RM, O'Hanlon TP, Hoffman EP, Peterson JM, **Miller FW**, Rider LG, Nagaraju K. A novel estrogen receptor 1-sphingomyelin phosphodiesterase acid like 3B pathway mediates rituximab response in myositis patients. *Rheumatology (Oxford).* 2022. Epub 20221208. doi: 10.1093/rheumatology/keac687. PMID: 36478205; PMCID: PMC Journal – In Process.
218. Rothwell S, Amos CI, **Miller FW**, Rider LG, Lundberg IE, Gregersen PK, Vencovsky J, McHugh N, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Molberg O, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker JL, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Wedderburn LR, Chinoy H, Lamb JA, Myositis Genetics C. Identification of Novel Associations and Localization of Signals in Idiopathic Inflammatory Myopathies Using Genome-Wide Imputation. *Arthritis Rheumatol.* 2022. Epub 20221229. doi: 10.1002/art.42434. PMID: 36580032; PMCID: PMC Journal – In Process.
219. Lundberg IE, **Miller FW**, Rider LG, Werth VP, Tjärnlund A, Bottai M. Response to: 'Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups'' by Irfan et al. *Ann Rheum Dis.* 2023;82(2):e41. Epub 20210113. doi: 10.1136/annrheumdis-2020-219436. PMID: 33441297; PMCID: PMC Journal – In Process.
220. Sherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, Pak K, Kishi T, Flegel WA, Targoff IN, **Miller FW**, Lundberg IE, Rider LG, Mammen AL, Childhood Myositis Heterogeneity Collaborative Study G. Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. *Rheumatology (Oxford).* 2023;62(S12):SI226-SI34. doi: 10.1093/rheumatology/keac428. PMID: 35961028; PMCID: PMC9949705.
221. Zhou D, King EH, Rothwell S, Krystufkova O, Notarnicola A, Coss S, Abdul-Aziz R, Miller KE, Dang A, Yu GR, Drew J, Lundstrom E, Pachman LM, Mamyrova G, Curiel RV, De Paepe B, De Bleecker JL, Payton A, Ollier W, O'Hanlon TP, Targoff IN, Flegel WA, Sivaraman V, Oberle E, Akoghlanian S, Driest K, Spencer CH, Wu YL, Nagaraja HN, Ardoin SP, Chinoy H, Rider LG, **Miller FW**, Lundberg IE, Padyukov L, Vencovsky J, Lamb JA, Yu CY, for MI. Low copy numbers of complement C4 and C4A deficiency are risk

- factors for myositis, its subgroups and autoantibodies. *Ann Rheum Dis*. 2023;82(2):235-45. Epub 20220928. doi: 10.1136/ard-2022-222935. PMID: 36171069; PMCID: PMC9887400.
222. Ayala-Ramirez M, MacNell N, McNamee LE, McGrath JA, Akhtari FS, Curry MD, Dunnon AK, Fessler MB, Garantziotis S, Parks CG, Fargo DC, Schmitt CP, Motsinger-Reif AA, Hall JE, **Miller FW**, Schurman SH. Association of distance to swine concentrated animal feeding operations with immune-mediated diseases: An exploratory gene-environment study. *Environ Int*. 2023;171:107687. Epub 20221209. doi: 10.1016/j.envint.2022.107687. PMID: 36527873; PMCID: PMC Journal – In Process.
223. Kim H*, Saygin D*, Douglas C, Wilkerson J, Erman B, Pistorio A, McGrath JA, Reed AM, Oddis CV, Bracaglia C, van Royen-Kerkhof A, Bica B, Dolezalova P, Ferriani VPL, Flato B, Bernard-Medina AG, Herlin T, **Miller FW**, Vencovsky J, Ruperto N, Aggarwal R, Rider LG, International Myositis A, Clinical Studies G, Paediatric Rheumatology ITO. Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles. *Rheumatology (Oxford)*. 2023. Epub 20230317. doi: 10.1093/rheumatology/kead111. PMID: 36929918; PMCID: PMC Journal – In Process. *These authors contributed equally.
224. Saygin D*, Kim H*, Douglas C, Erman B, Wilkerson J, McGrath JA, Oddis CV, Lundberg IE, Amato AA, Garcia-De La Torre I, Chinoy H, Fiorentino D, Chung L, Song YW, **Miller FW**, Ruperto N, Vencovsky J, Aggarwal R, Rider LG, International Myositis A, Clinical Studies G. Performance of the 2016 ACR-EULAR myositis response criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles. *Rheumatology (Oxford)*. 2023. Epub 20230317. doi: 10.1093/rheumatology/kead110. PMID: 36929923; PMCID: PMC Journal – In Process. *These authors contributed equally.
225. Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, **Miller FW**, Rider LG*, Mammen AL*. Anti-Sp4 autoantibodies co-occur with anti-TIF1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis. *Arthritis Rheumatol*. 2023. Epub 20230330. doi: 10.1002/art.42512. PMID: 36996276; PMCID: PMC Journal – In Process. *These authors contributed equally.
226. Johnson C, Schiffenbauer AI, **Miller FW**, Perin J, Danoff SK, Diwadkar AR, Joo J, Himes BE, Meyer NJ, Myositis ILDSG. Human Leukocyte Antigen Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy. *Am J Respir Crit Care Med*. 2023;207(5):619-22. doi: 10.1164/rccm.202206-1116LE. PMID:

36269757; PMID: PMC Journal – In Process.

227. Karasawa R, Yudoh K, Sato T, Tanaka M, Sabbagh SE, Flegel WA, Mammen AL, Jarvis JN*, Rider LG*; **Childhood Myositis Heterogeneity Study Group**. Association of Anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis. *Rheumatology (Oxford)*. 2023 May 5:kead203. doi: 10.1093/rheumatology/kead203. Online ahead of print. PMID: 37144941; PMID: PMC Journal – In Process. *These authors contributed equally.
228. Weisman MH, S Oleg, H Seok Kim, JK Hou, **FW Miller** and CF Dillon. Inflammatory Bowel Disease Prevalence: Surveillance data from the U.S. National Health and Nutrition Examination Survey. *Preventive Medicine Reports*. 2023 Mar 9;33:102173. doi: 10.1016/j.pmedr.2023.102173. eCollection 2023 Jun. PMID: 37223580; PMID: PMC10201824
229. Ward J, Ambatipudi M, O'Hanlon TP, Smith MA, de Los Reyes M, Schiffenbauer A, Rahman S, Zerrouki K, **Miller FW**, Sanjuan MA, Li JL, Casey KA, Rider LG. Shared and Distinctive Transcriptomic and Proteomic Pathways in Adult and Juvenile Dermatomyositis. *Arthritis Rheumatol*. 2023 May 25. doi: 10.1002/art.42615. Online ahead of print. PMID: 37229703; PMID: PMC Journal – In Process.
230. Cervantes BA, Gowda P, Rider LG, **Miller FW**, Chen MY, Schiffenbauer A. Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis. *Rheumatology (Oxford)*. 2023 Jun 7:kead256. doi: 10.1093/rheumatology/kead256. Online ahead of print. PMID: 37286372; PMID: PMC Journal – In Process.
231. Dinse GE, Zheng B, Co CA, Parks CG, Weinberg CR, **Miller FW**, Chan EK. Anti-Dense Fine Speckled 70 (DFS70) Autoantibodies: Correlates and Increasing Prevalence in the United States. *Front Immunol*. 2023, In press

Books, Book Chapters, Letters and Reviews

1. **Miller FW**, Baker JR, Jr., Burman KD, Steinberg AD. Thyroid-stimulating and thyrotropin binding-inhibiting immunoglobulins in patients with systemic lupus erythematosus. In: Pryzanski W, Seligman M, editors. *Clinical Immunology*. Amsterdam: Elsevier Science Publishers; 1987. p. 73-6.

2. Allaway GP, Srinivasappa J, **Miller FW**, Prabahakar BS, Notkins AL. Autoantibody production by human B lymphocytes which spontaneously proliferate. In: Levine PH, editor. *Epstein-Barr Virus and Human Diseases*. Clifton, New Jersey: Humana Press; 1987. p. 287-91.
3. Cronin ME, **Miller FW**, Plotz PH. Polymyositis and Dermatomyositis. Chapter 21 in *Primer on the Rheumatic Diseases*, 1988; 9th Edition, Springer, New York, Ed. HR Schumaker, Jr.
4. Plotz PH, **Miller FW**. Animal models of myositis. *Mt Sinai J Med*. 1988;55(6):501-5. PubMed PMID: 3068539.
5. Plotz PH, Cronin ME, Love LA, **Miller FW**, McClintock P, Smith DW. Picornavirus-initiated chronic inflammation, pp. 145-151, in *New Antiviral Strategies*, 1988, Churchill Livingstone, Edinburgh, Ed. SR Norrby.
6. **Miller FW**. Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. *Curr Opin Rheumatol*. 1991;3(6):902-10. doi: 10.1097/00002281-199112000-00002. PMID: 1772743.
7. Tsui FWL, **Miller FW**. Idiopathic Inflammatory Myopathies. Chapter 23 in *The Molecular Pathology of Autoimmunity*, 1993; Harwood Academic Publishers, Newark, Eds. CA Bona, K Siminovitch, AN Theofilopoulos, M Zanetti.
8. **Miller FW**. Seasonal, geographic, clinical and immunogenetic associations of the myositis-specific autoantibodies. *Systeme Nerveux, Muscles et Maladies Systemiques*, 1993; Expansion Scientifique Francaise, Paris, Ed. G Serratrice.
9. Plotz PH, Leff RL, **Miller FW**. Inflammatory and Metabolic Myopathies. Chapter 14, pp. 127-131, in *Primer on the Rheumatic Diseases*, 1993; 10th Edition, Ed. HR Schumacher Jr.
10. Plotz PH, **Miller FW**. Etiology and Pathogenesis of Inflammatory Muscle Disease. Chapter 13, pp. 13.1-13.10, in *Rheumatology*, 1994; Mosby, Gower Medical Publishing, London, Eds. JH Klippel, DA Dieppe.
11. **Miller FW**. Classification and prognosis of inflammatory muscle disease. *Rheum Dis Clin North Am*. 1994;20(4):811-26. PubMed PMID: 7855323.
12. Pachman LM, **Miller FW**. Idiopathic Inflammatory Myopathies: Dermatomyositis, Polymyositis and Related Disorders. Chapter 41, pp. 791-804, in *Samter's Immunologic Diseases*, 1995; Little, Brown and Company, Boston, Eds. M Frank; K Austen, H Claman, E Unanue.

13. **Miller FW.** *Myositis - Patient Information Pamphlet.* Arthritis Foundation, Atlanta, pp. 1-8, 1995.
14. Love LA, **Miller FW.** Understanding the idiopathic inflammatory myopathies. *Contemporary Internal Med.* 1995; 7:29-43.
15. **Miller FW.** Genetics of autoimmune diseases. *ExpClin Immunogenet.* 1995;12(3):182-90. doi: 10.1159/000424870. PMID: 8534504.
16. **Miller FW,** Sawyer WR. What Causes Myositis? *National Myositis Association Newsletter* 1996; 16:2-3.
17. **Miller FW.** Commentary on correlation of anti-synthetase levels with disease course in a patient with interstitial lung disease and elevation of muscle enzymes. *J Clin Rheum.* 1996; 2:189-191.
18. **Miller FW.** Anti-Signal Recognition Particle Autoantibodies. Pp. 735-740, in *Autoantibodies*, 1996; Elsevier Sciences BV, Amsterdam, Eds. JB Peters, Y Shoenfeld.
19. **Miller FW.** Intravenous immunoglobulin in polymyositis/dermatomyositis. Pp. 205-212, in *Proceedings: Early Decisions in DMARD Development IV. Biologic Agents in Autoimmune Disease*, Arthritis Foundation, 1996; Atlanta, Ed. V Strand.
20. **Miller FW.** Inflammatory myopathies: Polymyositis, dermatomyositis, and related conditions. Chapter 73, pp. 1407-1432, in *Arthritis and Allied Conditions: A Textbook of Rheumatology*, 1996; Williams & Wilkins, Baltimore, Ed. W Koopman.
21. **Miller FW.** Editorial overview: Myositis and myopathies. *Curr Opin Rheumatol.* 1996; 8:491-494.
22. **Miller FW,** Urnovitz H. Genetic factors affecting development of autoimmunity. Pp. 35-37, in *Institute of Medicine Vaccine Safety Forum.* National Academy Press, 1997; Washington, DC.
23. Epstein S, **Miller FW.** What's in a Name? (letter). *The Scientist*, 1997; 11:9.
24. **Miller FW.** Editorial overview: Myositis and myopathies. *Curr Opin Rheumatol.* 1997; 9:471-74.
25. Plotz PH, **Miller FW.** Etiology and pathogenesis of inflammatory muscle disease. Chapter 14, pp. 14.1-14.10, in *Rheumatology*, 1997; Second Edition, Mosby, Gower Medical Publishing, London, Eds. JH Klippel and PA Dieppe.

26. **Miller FW.** Editorial overview: Myositis and myopathies. *Curr Opin Rheumatol.* 1998; 10:499-503.
27. **Miller FW.** Genetics of environmentally-associated rheumatic diseases. Chapter 4, pp. 33-40, in *Rheumatic Diseases and the Environment*, 1999; Chapman & Hall Medical Publishers, New York, Eds. L Kaufman and J Varga.
28. Cooper GS, **Miller FW**, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. *Environ Health Perspect.* 1999;107 Suppl 5(Suppl 5):693-700. doi: 10.1289/ehp.99107s5693. PMID: 10502533; PMCID: PMC1566257.
29. Rider LG, **Miller FW.** Idiopathic inflammatory muscle disease: clinical aspects. *Baillieres Best Pract Res Clin Rheumatol.* 2000;14(1):37-54. doi: 10.1053/berh.1999.0076. PMID: 10882213.
30. **Miller FW**, Wortmann RL, Robbins L. Myositis - Patient Information Pamphlet. Arthritis Foundation, Atlanta, 2000.
31. Shamim EA, Rider LG, **Miller FW.** Update on the genetics of the idiopathic inflammatory myopathies. *Curr Opin Rheumatol.* 2000;12(6):482-91. doi: 10.1097/00002281-200011000-00002. PMID: 11092196.
32. **Miller FW.** Inflammatory myopathies: Polymyositis, dermatomyositis, and related conditions. Chapter 78, pp. 1562-1589, in *Arthritis and Allied Conditions, A Textbook of Rheumatology*, 2000; 14th Edition, (volume 2), Lippincott, Williams, and Wilkins, Philadelphia, Ed. W Koopman.
33. Plotz PH, **Miller F**, Hoffman E, Casciola-Rosen L, Rosen A. Workshop on inflammatory myopathy Bethesda, 5-6 April 2000. *Neuromuscul Disord.* 2001;11(1):93-5. doi: 10.1016/s0960-8966(00)00178-4. PMID: 11166171.
34. Pachman LM, **Miller FW.** Idiopathic inflammatory myopathies: Dermatomyositis, polymyositis and related disorders. Chapter 41, pp. 791-804, in *Samter's Immunologic Diseases*, 6th Edition, 2001; Little, Brown and Company, Boston, Eds. KF Austen, MM Frank, JP Atkinson, H Cantor.
35. Richter-Reichhelm H, Stahlmann R, Smith E, Van Loveren H, Altoff J, Bass R, Corsini E, Dayan A, Dean JH, Descotes J, Emmendorffer A, Eppler R, Hall AJ, Herrman JL, Lovik M, Luster MI, **Miller FW**, Riecke K, Schoning G, Schulte A, Smialowicz RJ, Ulrich P, Vohr HW, Vos JG, White KL. Approaches to risk assessment of immunotoxic effects of chemicals. Meeting report. *Toxicology.* 2001; 161:213-28.

36. Plotz PH, **Miller FW**. Myositis classics: An historical perspective at the millennium. Chapter 15, pp. 222-235, in *Classic Papers in Rheumatology*, 2001; Martin Dunitz, London. Ed. P Dieppe et al.
37. Cooper GS, **Miller FW**, Germolec DR. Occupational exposures and autoimmune diseases. *Int Immunopharmacol*. 2002;2(2-3):303-13. doi: 10.1016/s1567-5769(01)00181-3. PMID: 11811933.
38. **Miller FW**, Editor. Idiopathic inflammatory myopathies, *Rheum Dis Clin North Am*. 2002; 28(4).
39. **Miller FW**. Preface to idiopathic inflammatory myopathies. *Rheum Dis Clin North Am*. 2002; 28(4): XI-XIII, Ed. FW Miller.
40. **Miller FW**. Myositis. Chapter 36, pp. 603-620, in *Targeted Therapies in Rheumatology*. 2003; Martin Dunitz, London. Eds. JS Smolen and PE Lipsky.
41. Henderson C, **Miller FW**, Minor M. Wortmann RL. Myositis – Patient information pamphlet. Arthritis Foundation, 2003; Atlanta, pp. 1-7.
42. **Miller FW**. Inflammatory Myopathies: Polymyositis, dermatomyositis, and related conditions. Chapter 15, pp. 182-198, in *Clinical Primer of Rheumatology*. 2003; Lippincott, Williams, and Wilkins, Philadelphia, Eds. WJ Koopman, DW Boulware, GR Huedebert.
43. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, **Miller FW**, International Myositis A, Clinical Studies G. Defining Clinical Improvement in Adult and Juvenile Myositis. *J Rheumatol*. 2003;30(3):603-17. PMID: 12610824.
44. Nagaraju K, Plotz PH, **Miller FW**. Etiology and pathogenesis of inflammatory muscle disease. Chapter 138, pp. 1523-1535, in *Rheumatology*, Third Edition, 2003; Mosby, Elsevier Limited, London, Eds. MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman.
45. **Miller FW**, Rider LG, Plotz PH, Isenberg DA, Oddis CV. Diagnostic criteria for polymyositis and dermatomyositis. *Lancet*. 2003;362(9397):1762-3; author reply 3. doi: 10.1016/s0140-6736(03)14862-3. PMID: 14643132.
46. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, **Miller FW**. International Myositis Assessment and Clinical Studies Group. Defining clinical improvement in adult and juvenile myositis. *J Rheumatol*. 2003; 30(3):603-17.

47. Chanock SJ, Foster CB, **Miller FW**, O'Hanlon TP. HLA-A, -B, -Cw, -DQA1 and -DRB1 alleles in a Caucasian population from Bethesda, USA. *Human Immunology*. 65: Elsevier; 2004. p. 1211-23.
48. Chanock SJ, Foster CB, **Miller FW**, O'Hanlon TP. HLA-A, -B, -Cw, -DQA1 and DRB1 in an African American population from Bethesda, USA. *Human Immunology*. 65: Elsevier; 2004. p. 1223-35.
49. **Miller FW**. Polymyositis and Dermatomyositis, Chapter 283, pp. 1680-1684, in *Cecil Textbook of Medicine*, 22nd Edition, 2004; Saunders, Philadelphia, Eds. L Goldman, D Ausiello.
50. **Miller FW**, Rider LG, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV. Polymyositis: an overdiagnosed entity. *Neurology*. 2004;63(2):402; author reply 3. doi: 10.1212/wnl.63.2.402. PMID: 15277657.
51. Sarkar K, **Miller FW**. Possible roles and determinants of microchimerism in autoimmune and other disorders. *Autoimmun Rev*. 2004;3(6):454-63. doi: 10.1016/j.autrev.2004.06.004. PMID: 15351311.
52. **Miller FW**. Myositis. Chapter 10, pp. 187-201, in *The Year in Rheumatic Disorders*, 2004; Volume 4, Clinical Publishing, Oxford, Eds. R Madhok and H Capell.
53. Sarkar K, **Miller FW**. Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. *Autoimmunity*. 2004;37(4):291-4. doi: 10.1080/08916930410001710839. PMID: 15518044.
54. **Miller FW**. Clinical presentation and therapy of the idiopathic inflammatory myopathies. *J Musculoskelet Pain*. 2004; 12:85-91.
55. Kerns W, Schwartz L, Blanchard K, Burchiel S, Essayan D, Fung E, Johnson R, Lawton M, Loudon C, MacGregor J, **Miller F**, Nagarkatti P, Robertson D, Snyder P, Thomas H, Wagner B, Ward A, Zhang J. Drug-induced vascular injury--a quest for biomarkers. *Toxicol Appl Pharmacol*. 2005;203(1):62-87. doi: 10.1016/j.taap.2004.08.001. PMID: 15694465.
56. **Miller FW**. Inflammatory Myopathies: Polymyositis, dermatomyositis, and related conditions. Chapter 75 (volume 2), pp. 1593-1620, in *Arthritis and Allied Conditions - A Textbook of Rheumatology*, 2005; 15th Edition, Lippincott Williams & Wilkins, Philadelphia, Eds. W Koopman, L Moreland.
57. Huber AM, **Miller FW**, Rider LG. Validation and clinical significance of the Childhood Myositis Assessment Scale – Reply. *Arthritis Rheum*. 2005; 52:368-369 (letter).

58. **Miller FW.** Non-infectious Environmental Agents and Autoimmunity. Chapter 23, pp. 297-308, in *The Autoimmune Diseases*, 2006; 4th Edition, Elsevier, Boston, Eds. NR Rose, IR Mackay.
59. **Miller FW.** Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis? *Nat Clin Pract Rheumatol.* 2006 Mar;2(3):130-1. doi: 10.1038/ncprheum0137. PMID: 16932671.
60. O'Hanlon TP, **Miller FW.** The Idiopathic Inflammatory Myopathies (IIM): HLA polymorphisms distinguish patients with different clinical phenotypes and myositis-specific autoantibodies, *ASHI Quarterly* 2006; Fourth quarter: 98-100.
61. **Miller FW.** How do we best define autoantibodies? *Ann Rheum Dis*, 2006; eLetter.
62. Cooper GS, **Miller FW.** Environmental influences on autoimmunity and autoimmune diseases. Chapter 25, pp. 437-454, in *Immunotoxicology and Immunopharmacology*, 2007; CRC Press, New York, 3rd Edition, Eds. R Luebke et al.
63. Rider LG, Pachman LM, **Miller FW**, Bollar H. Introduction. Pp. 1-8, *Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers.* 2007; The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
64. Rider LG, **Miller FW.** What Is Juvenile Myositis? Chapter 1, pp. 9-22, in *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
65. **Miller FW**, Lovell D. New Therapies on the Horizon. Chapter 15, pp. 207-216, in *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
66. Lovell D, **Miller FW.** How We Learn About Juvenile Myositis? Chapter 39, pp. 423-434, in *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
67. Gourley M, **Miller FW.** Mechanisms of disease: Environmental factors in the pathogenesis of rheumatic disease. *Nature clinical practice Rheumatology.* 2007;3(3):172-80. doi: 10.1038/ncprheum0435. PMID: 17334340.

68. **Miller FW**. Myositis, Chapter 38, pp. 467-484, in *Contemporary Targeted Therapies in Rheumatology*, 2007; Informa Healthcare, London, Eds. JS Smolen and PE Lipsky.
69. Rider LG, **Miller FW**. Idiopathic inflammatory myopathies, Pathology and pathogenesis, Chapter 18B, pp. 368-374, in *Primer on the Rheumatic Diseases*, 13th Edition, 2007; Springer, Arthritis Foundation, New York, Eds. J. Klippel et al.
70. **Miller FW**, Cooper GS. Environmental aspects of lupus, Chapter 3, pp. 21-33, in *Dubois' Lupus Erythematosus*. 2007; 7th Edition; Lippincott Williams and Wilkins, Philadelphia, Eds. D Wallace, B Hahn.
71. **Miller FW**. Idiopathic inflammatory myopathies. Chapter 15.6, in *American College of Physicians ACP Medicine Online*, 2007 WebMD Professional Publishing, New York, Ed. S. Ruddy.
72. Rider LG, Lachenbruch P, Isenberg DA, **Miller FW**. Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al. *Arthritis Rheum.* 2008;59(8):1197-8; author reply 8-9. doi: 10.1002/art.23919. PMID: 18668578.
73. **Miller FW**. Polymyositis and dermatomyositis, Chapter 290, pp. 2045-2049, in *Cecil Textbook of Medicine*, 2008; 23rd Edition; Saunders, Philadelphia, Eds. L Goldman, D Ausiello.
74. Dugan EM, Huber AM, **Miller FW**, Rider LG, International Myositis A, Clinical Studies G. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatol Online J.* 2009;15(2):1. Epub 20090215. doi. PMID: 19336018.
75. Dugan EM, Huber AM, **Miller FW**, Rider LG, International Myositis A, Clinical Studies G. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatol Online J.* 2009;15(2):2. Epub 20090215. doi. PMID: 19336019.
76. O'Hanlon TP, **Miller FW**. Genetic risk and protective factors for the idiopathic inflammatory myopathies. *Curr Rheumatol Rep.* 2009;11(4):287-94. Epub 2009/08/21. doi: 10.1007/s11926-009-0040-2. PMID: 19691932.
77. **Miller FW**. Classification of the idiopathic inflammatory myopathies, Chapter 2, pp. 15-28, in *The Inflammatory Myopathies*, 2009; Humana Press, Springer, New York, Ed. L Kagen.

78. Targoff IN, Oddis C, Plotz P, **Miller FW**, Gourley M. Inflammatory Myopathies. Pp. 191-199, in *A Clinician's Pearls and Myths in Rheumatology*, 2009; Springer, New York, Ed. J Stone.
79. Rider LG, **Miller FW**. Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface? *Arthritis Rheum*. 2010;62(9):2619-22. doi: 10.1002/art.27525. PMID: 20506242; PMCID: PMC2946445.
80. **Miller FW**. Management of Inflammatory Muscle Disease. Chapter 146, pp. 1417-78, in *Rheumatology*, 5th Edition, 2011; Elsevier, Philadelphia, Eds. MC Hochberg et al.
81. **Miller FW**. Environmental agents and autoimmune diseases. *Adv Exp Med Biol*. 2011;711:61-81. doi: 10.1007/978-1-4419-8216-2_6. PMID: 21627043.
82. Gan L, **Miller FW**. State of the art: what we know about infectious agents and myositis. *Curr Opin Rheumatol*. 2011;23(6):585-94. doi: 10.1097/BOR.0b013e32834b5457. PMID: 21885972.
83. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, **Miller FW**. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). *Arthritis Care Res (Hoboken)*. 2011;63 Suppl 11(0 11):S118-57. doi: 10.1002/acr.20532. PMID: 22588740; PMCID: PMC3748930.
84. **Miller FW**. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. *Ann Rheum Dis*. 2012;71 Suppl 2:i82-5. doi: 10.1136/annrheumdis-2011-200587. PMID: 22460145.

85. **Miller FW**, Oddis CV. Vasculitis in the Idiopathic Inflammatory Myopathies, Chapter 39, pp. 433-40, in *Inflammatory Diseases of Blood Vessels*, 2012; 2nd Edition, Blackwell Publishing Ltd. Oxford. Eds. GS Hoffman, CM Weyand, CA Langford, and JJ Goronzy.
86. Whitt IZ, **Miller FW**. Inflammatory myopathies: polymyositis, dermatomyositis and related conditions. Chapter 13, pp. 455-481, in *Lippincott's Primary Care Rheumatology*, 2012; Lippincott, Williams and Wilkins, Philadelphia, Eds. DW Boulware and GR Heudebert.
87. **Miller FW**, Pollard KM, Parks CG, Germolec DR, Leung PS, Selmi C, Humble MC, Rose NR. Criteria for environmentally associated autoimmune diseases. *J Autoimmun.* 2012;39(4):253-8. Epub 20120706. doi: 10.1016/j.jaut.2012.05.001. PMID: 22771005; PMCID: PMC3468712.
88. **Miller FW**. Polymyositis and dermatomyositis, Chapter 277, pp. 1716-1720, in *Goldman's Cecil Medicine*, 24th Edition, 2012; Saunders, Philadelphia, Eds. L Goldman, D Ausiello.
89. **Miller FW**, Alfredsson L, Costenbader KH, Kamen DL, Nelson LM, Norris JM, De Roos AJ. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. *J Autoimmun.* 2012;39(4):259-71. Epub 20120625. doi: 10.1016/j.jaut.2012.05.002. PMID: 22739348; PMCID: PMC3496812.
90. **Miller FW**. Idiopathic Inflammatory Myopathies, Chapter 6, in *American College of Physicians ACP Medicine Online*, 2013, WebMD Professional Publishing, New York, Ed. E Nabel.
91. Mahler M, **Miller FW**, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. *Autoimmun Rev.* 2014;13(4-5):367-71. Epub 20140111. doi: 10.1016/j.autrev.2014.01.022. PMID: 24424190; PMCID: PMC3970575.
92. **Miller FW**. Management of Inflammatory Muscle Disease. Chapter 146, in *Rheumatology*, 6th Edition, 2014; Saunders, Philadelphia, Eds. MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman.
93. Rider LG, Dankó K, **Miller FW**. Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research. *Curr Opin Rheumatol.* 2014;26(6):724-41. doi: 10.1097/bor.0000000000000119. PMID: 25225838; PMCID: PMC5081267.

94. **Miller FW.** Non-infectious Environmental Agents and Autoimmunity, Chapter 21, pp. 283-295, in *The Autoimmune Diseases*, 5th Edition, 2014; Academic Press, Boston; Eds. NR Rose, IR Mackay.
95. Schiffenbauer AS, **Miller FW.** Idiopathic Inflammatory Myopathies. Chapter 8, pp. 1-15, in *Scientific American Medicine*, 2015; Decker Intellectual Properties, Hamilton, Ontario, Ed. EG Nabel.
96. Rider LG, Lindsley CB, **Miller FW.** Juvenile Dermatomyositis, Chapter 26, pp. 351-383, in *Textbook of Pediatric Rheumatology, 7th edition*, 2015; Elsevier, Philadelphia. Eds. R Petty, R Laxer, C Lindsley, L Wedderburn.
97. Lundberg IE, **Miller FW**, Tjarnlund A, Bottai M. Diagnosis and classification of idiopathic inflammatory myopathies. *J Intern Med.* 2016;280(1):39-51. doi: 10.1111/joim.12524. PMID: 27320359; PMCID: PMC5021058.
98. Rider LG, **Miller FW.** Environmental Factors in Pediatric Systemic Autoimmune Diseases: There's Still Much to Learn. *The Rheumatologist* 2017; 11(3):49-53.
99. Rider LG, **Miller FW.** Outcome Assessment in the Idiopathic Inflammatory Myopathies. Chapter 16, pp. 161-170. In *Myositis (Oxford Rheumatology Library)*, 2018, Oxford University Press, Oxford. Eds. H Chinoy and R Cooper.
100. **Miller FW**, Lamb JA, Schmidt J, Nagaraju K. Risk factors and disease mechanisms in myositis. *Nat Rev Rheumatol.* 2018;14(5):255-68. Epub 2018/04/21. doi: 10.1038/nrrheum.2018.48. PMID: 29674613; PMCID: PMC6745704.
101. Schiffenbauer AS, **Miller FW.** Management of Inflammatory Muscle Disease, in *Rheumatology*, Chapter 159, pp. 1322-1328, 7th Edition, 2018. Saunders, Philadelphia, Eds. MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman.
102. Schiffenbauer AS, **Miller FW.** Non-infectious Environmental Agents and Autoimmunity, Chapter 20, pp. 345-362, in *The Autoimmune Diseases, 6th Edition*, 2019. Academic Press, Boston; Eds. NR Rose, IR Mackay.
103. Schiffenbauer AS, **Miller FW.** Introduction to Myositis, Chapter 1, pp1-6. In *Managing Myositis: A Practical Guide*, 2020, Springer, New York. Eds. R Aggarwal and C Oddis.
104. **Miller FW.** Slicing and Dicing Myositis for Cures and Prevention, *Nat Rev Rheumatol*, 2021,17(5):255-256.

105. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, **Miller FW**. Idiopathic inflammatory myopathies. *Nat Rev Dis Primers*. 2021 Dec 2;7(1):86. doi: 10.1038/s41572-021-00321-x. PMID: 34857798; PMCID: PMC Journal – In Process.
106. Isenberg DA, Chinoy H, Dimachkie MM, **Miller FW**, Rider LG. The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). *Clin Exp Rheumatol*. 2022;40(2):214-8. Epub 20220120. doi: 10.55563/clinexprheumatol/yg743i. PMID: 35225220; PMCID: PMC Journal – In Process.
107. Dellaripa PF, Bush T, **Miller FW**, Feldman CH. The Climate Emergency and the Health of Our Patients: The Role of the Rheumatologist. *Arthritis Rheumatol*. 2022 Jun 28. doi: 10.1002/art.42279. Epub ahead of print. PMID: 35762821; PMCID: PMC Journal – In Process.
108. **Miller FW**. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. *Curr Opin Immunol*. 2023;80:102266. Epub 20221126. doi: 10.1016/j.coi.2022.102266. PMID: 36446151; PMCID: PMC9918670.
109. Lundberg IE, **Miller FW**. Diagnostic and Classification Criteria for Dermatomyositis, Polymyositis, and Immune-mediated Necrotizing Myopathies. *The Myositis Handbook: An Inclusive Guide to the Inflammatory Myopathies*, 2023 in press. Jaypee Brothers Medical Publisher, London, Eds. L Christopher-Stine and I Lundberg.
110. Dellaripa PF, Bush T, **Miller FW**, Feldman CH. Response to Letter. *Arthritis Rheumatol*. 2023 Mar 2. doi: 10.1002/art.42488. Epub ahead of print. PMID: 36862394; PMC Journal – In Process.
111. Oddis CV, Limaye V, **Miller FW**, and Christopher-Stine L. Inflammatory Myopathies, Chapter 16, pp 261-274. *In A Clinician's Pearls and Myths in Rheumatology, 2nd Ed*, 2023, Springer, New York, Ed. J Stone.